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1 ABBREVIATIONS 
aCGH   array comparative genomic hybridization 
ATCC  American Type Culture Collection 
BAC   bacterial artificial chromosome 
cCGH    chromosomal comparative genomic hybridization 
cDNA   complementary DNA 
CGH   comparative genomic hybridization 
Cy3   cyanine 3 
Cy5   cyanine 5 
DNA   deoxyribonucleic acid 
FAP   familial adenomatous polyposis 
FC   fold change 
FISH  fluorescent in situ hybridization 
HDGC   hereditary diffuse gastric carcinoma 
HNPCC  hereditary nonpolyposis colon cancer 
IHC   immunohistochemistry 
mRNA   messenger RNA 
MSI   microsatellite instability 
qRT-PCR quantitative reverse transcription polymerase chain reaction 
RNA   ribonucleic acid 
rRNA    ribosomal RNA 
SNP   single nucleotide polymorphism 
TMA   tissue microarray 
TRAC   transcript analysis with aid of affinity capture 
WHO   World Health Organization 
 
All gene symbols used in the text can be found at 
http://www.ncbi.nlm.nih.gov/entrez.
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3 ABSTRACT 
Gene copy number alterations play a key role in the development of gastric cancer, 
and a change in gene copy number is one of the fundamental mechanisms for a 
cancer cell to control the expression of potential oncogenes and tumor suppressor 
genes.  Several genomic alterations have been identified in gastric cancer, but the 
major mechanisms contributing to initiation and progression of gastric cancer remain 
poorly known. 
This thesis aims at clarifying the complex genomic alterations of gastric cancer to 
identify novel molecular biomarkers for diagnostic purposes as well as for targeted 
treatment. To highlight genes of potential biological and clinical relevance, we 
carried out a systematic microarray-based survey of gene expression and copy 
number  levels  in  primary  gastric  tumors  and  gastric  cancer  cell  lines.  Results  were  
validated using immunohistochemistry, affinity-based transcript assay, and real-time 
qRT-PCR.  
Multiple chromosomal regions with recurrent copy number alterations were 
detected. The most frequent chromosomal alterations included gains at 1q, 5, 7q, 
8q, 14q, 17q, 19q, 20, and X, and losses at 4q, 9p, 18q, 21q, and Xq. Distinctive 
patterns of copy number alterations were detected for different histological 
subtypes  and  for  cancers  located  in  different  parts  of  the  stomach.  The  impact  of  
copy number alterations on gene expression was significant, as 6-10% of genes 
located  in  the  regions  of  gains  and  losses  also  showed  concomitant  alterations  in  
their expression. Independent genome-wide gene expression analysis of Finnish and 
Japanese gastric tumors revealed an additional set of genes that was differentially 
expressed in cancerous gastric tissues compared with normal tissue. Thus, using an 
integrative microarray analysis, we identified several genes that may be critically 
important for gastric carcinogenesis. Functional validation of these genes may lead 
to novel biomarkers for gastric cancer diagnosis and targeted therapy.    
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4 INTRODUCTION 
Gastric cancer is one the most common malignancies worldwide (Parkin et al., 2005). 
Multiple genomic alterations, such as chromosomal aberrations, mutations, and 
changes in gene expression underlie gastric carcinogenesis (Keller et al., 2005; Stock 
and Otto, 2005; Hamilton and Meltzer, 2006). There are two distinct histological 
subtypes of gastric carcinoma, intestinal and diffuse (Laurén, 1965), which differ in 
their epidemiology, pathogenesis, genetic profile, and clinical outcome (Munoz et al. 
1968; Hamilton and Aaltonen, 2000). 
Most gastric cancers are sporadic and occur due to spontaneous somatic 
mutations,  whereas  only  about  8-10%  of  all  gastric  cancer  cases  are  caused  by  
inherited predisposing mutations (Caldas et al., 1999; Hamilton and Aaltonen, 2000).  
The most common underlying cause of these familial gastric cancers is a germline 
mutation in the E-cadherin gene (CDH1), which predisposes to the hereditary diffuse-
type gastric cancer (Fuchs and Mayer, 1995; Gayther et al., 1998; Guilford et al., 
1998).  
Many chromosomal regions exhibit copy number gains or losses in gastric cancer 
(Yang et al., 2007a; Tsukamoto et al., 2008), and these regions include genes known 
to be involved in the formation of gastric carcinomas such as APC, BCL2, DCC, CCND1, 
and ERBB2 (Keller et al., 2005; Tamura et al., 2006). Some of these genes function as 
repressors of tumor formation, while others induce processes central to 
carcinogenesis such as cell growth and invasion.  
Due to the lack of  early  symptoms,  gastric  adenocarcinoma is  characterized by 
late stage diagnosis and unsatisfactory options for curative treatment (Hundahl et 
al., 2000; Green et al., 2002). Genomic profiling of gastric cancer will improve our 
understanding of the molecular alterations behind the initiation and progression of 
gastric cancer as well as enable the identification of new biomarkers for diagnosis 
and targeted treatment.  
 
Review of the Literature 
 
 10
5 REVIEW OF THE LITERATURE 
5.1 Gastric carcinoma 
5.1.1 Epidemiology and etiology 
Gastric cancer is the fourth most common cancer worldwide and the second most 
common cause of cancer-related death, inflicting 700,000 annual deaths globally 
(Parkin et al., 2005). There are considerable geographic differences in the incidence 
of gastric cancer. Low-risk areas include most Western industrialized countries, 
whereas high incidence rates are observed in Japan, Korea, China, South America, 
and Portugal (Parkin et al., 2005). The incidence of gastric cancer in Northern Europe 
is low compared with the high-incidence areas. In Finland, 724 new gastric cancer 
cases were diagnosed in 2006, and gastric cancer ranked sixth in mortality after lung, 
pancreas, breast, prostate, and colon cancers (Finnish Cancer Registry). 
Approximately 90% of gastric cancers are adenocarcinomas, tumors that 
originate  from  the  epithelial  cells  lining  the  stomach  (Kelley  and  Duggan,  2003).  
Gastric  cancers  are  thought  to  develop  in  response  to  a  combination  of  
environmental factors and genetic alterations. The single most common cause of 
gastric cancer is Helicobacter pylori infection, which has been classified as a class I 
carcinogen by the World Health Organization (WHO) since 1994. On average, 15-20% 
of patients infected with H. pylori develop gastric or duodenal ulcer disease and less 
than 1% gastric adenocarcinomas (Suerbaum and Michetti, 2002). Other risk factors 
include dietary factors, such as diets rich in salt, smoked or poorly preserved foods, 
as well as behavioral factors, such as cigarette smoking. On the other hand, diets rich 
in fruit and vegetables are associated with a reduced risk of gastric cancer (Ramón et 
al., 1993; Huang et al., 2000). 
The majority of gastric carcinomas are sporadic. However, inactivating 
germline mutations in the CDH1 gene lead to an autosomal dominant predisposition 
to gastric carcinoma, the hereditary diffuse gastric carcinoma (HDGC), which 
represents about 1-3% of all gastric carcinomas (Grady et al., 2000; Hamilton and 
Aaltonen, 2000; Lynch et al., 2008). Germline mutations in CDH1 are associated with 
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a 70% life-time risk for diffuse gastric carcinoma (Lynch et al., 2008). Inherited 
familial components are detected also in intestinal-type gastric carcinomas since 
they  may  develop  as  a  part  of  the  hereditary  nonpolyposis  colon  cancer  (HNPCC)  
syndrome. In addition, patients with gastrointestinal polyposis syndromes, including 
familial adenomatous polyposis (FAP) and Peutz-Jeghers syndrome, are at a higher 
risk of developing gastric carcinomas. Moreover, an increased risk of gastric cancer 
has been observed for persons with blood type A (Fuchs and Mayer, 1995; Hamilton 
and Aaltonen, 2000), and mutations in the tumor suppressor genes BRCA1 and 
BRCA2 have been linked with a higher risk of gastric adenocarcinomas (Semba et al., 
1998; Johansson et al., 1999; Jakubowska et al., 2002).  
 
5.1.2 Classification and pathogenesis of gastric carcinoma 
Gastric tumors can be divided into different subgroups according to histology or 
growth site in the stomach. Several classification systems have been suggested for 
histological classification, but the most commonly used are those of Laurén (Laurén, 
1965) and the World Health Organization (WHO).  
 
5.1.2.1 Laurén’s classification 
Laurén’s classification divides gastric adenocarcinomas into two histological 
subtypes, intestinal and diffuse, which show both biological and epidemiological 
differences (Laurén, 1965; Fuchs and Mayer, 1995; Hamilton and Aaltonen, 2000). 
When identification of a gastric tumor as either intestinal or diffuse is not possible, 
the  histological  subtype  of  the  tumor  is  referred  to  as  a  mixed  type  gastric  
adenocarcinoma. 
The intestinal gastric cancer subtype represents about 50-60% of all gastric 
tumors, and is the predominant subtype in high-risk areas (Joensuu et al., 1999; 
Hamilton and Aaltonen, 2000; Milne et al., 2007). Intestinal gastric cancers are well-
differentiated and often exhibit components of the intestinal architecture such as 
tubular glandular structures (Fuchs and Mayer, 1995; Hamilton and Aaltonen, 2000). 
This subtype is more common in men and in older age groups (rare in patients aged 
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under 40 years), and it is more likely to be sporadic and related to environmental 
factors, including H. pylori infection, cigarette smoking, and diet (Laurén, 1965; 
Munoz et al., 1968; Hamilton and Aaltonen, 2000). Intestinal gastric cancers are 
thought to develop through an inflammation cascade initiated by H. pylori infection 
that leads to chronic gastritis, followed by atrophic gastritis, intestinal metaplasia 
(normal gastric epithelium replaced by intestine-like epithelium), dysplasia (benign, 
but precancerous epithelial lesion), and eventually full-blown gastric cancer (Yuasa, 
2003) (Figure 1).  
The diffuse subtype, by contrast, represents about 30-40% of gastric cancers 
and  is  more  common  in  younger  patients  (Joensuu  et  al., 1999; Hamilton and 
Aaltonen, 2000; Yuasa et al., 2003). These tumors are poorly differentiated, often 
grow as single cells or in small groups of cells, and are likely to infiltrate into the 
stomach wall. Similar to intestinal-type tumors, H. pylori infection has also been 
associated with diffuse-type gastric cancers (Figure 1) (Huang et al., 1998). However, 
H. pylori -associated precancerous lesions, such as intestinal metaplasia and 
dysplasia, are more characteristic of the intestinal subtype (Yuasa, 2003). In addition, 
a subset of diffuse gastric cancers (HDGC) is associated with germline mutations in 
the tumor suppressor gene CDH1,  which  encodes  for  E-cadherin,  a  cell-to-cell  
interaction molecule (Machado et al., 2001). E-cadherin regulates cell proliferation, 
especially through its interaction with β-catenin. Somatic mutations and loss of CDH1 
gene have also been detected in sporadic diffuse gastric tumors, but not in 
intestinal-type  gastric  tumors  (Becker  et  al.,  1994;  Machado  et  al., 2001; Yuasa, 
2003).  Epstein-Barr virus, suggested to increase the risk of gastric cancers, is 
observed in 7-20% of gastric carcinomas and more frequently in the diffuse subtype. 
The diffuse subtype usually has a worse prognosis than the intestinal subtype. While 
the incidence of intestinal gastric cancer has declined in the Western world during 
the past few decades, the incidence of diffuse gastric cancer has remained practically 
unchanged (Stock and Otto, 2005; Milne et al., 2007). 
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Figure 1. Model for gastric carcinogenesis (modified from Yuasa, 2003).  
 
5.1.2.2 WHO classification 
WHO’s classification divides gastric cancers into tubular, papillary, mucinous, and 
signet-ring cell gastric carcinomas. Tubular adenocarcinomas consist of branching 
tubules that vary in their diameter, and they may also contain acinar structures. 
Papillary adenocarcinomas are well-differentiated exophytic (growing outwards from 
the epithelium) carcinomas that sometimes show tubular differentiation. The degree 
of cellular atypia and mitotic index varies, but the invading edge of the tumor is 
usually clearly distinguishable from the surrounding structures and inflammatory 
cells may infiltrate the tumor. Mucinous adenocarcinomas contain extracellular 
mucinous pools and consist of two main growth patterns; glands lined by mucus-
secreting epithelium and interstitial mucin, and irregular cell clusters floating in 
mucinous lakes. Finally, in signet-ring cell carcinomas, the majority of the tumor 
consists of isolated or small groups of malignant cells that contain intracytoplasmic 
mucin. Signet-ring cell carcinomas often infiltrate into the surrounding tissues, and 
while the number of malignant cells is rather low, it is accompanied by prominent 
desmoplasia (growth of a dense fibrous tissue around the tumor). Signet-ring cell 
carcinomas resemble those classified as diffuse in Laurén’s classification (Hamilton 
and Aaltonen, 2000). 
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5.1.2.3 Classification according to growth site 
Gastric tumors can also be classified according to their growth site into tumors of the 
cardia, fundus, corpus, and antrum (Figure 2). Cardia surrounds the cardioesophagial 
junction, the opening of the esophagus to the stomach, whereas the fundus, corpus, 
and  antrum  represent  the  upper,  middle,  and  lower  thirds  of  the  stomach,  
respectively. The most common tumor site for gastric adenocarcinoma is the distal 
third of the stomach, the antrum. However, there has been a change in the 
anatomical location of stomach adenocarcinomas in the past few decades, with an 
increase in the number of tumors occurring in the proximal stomach and cardia and 
a decrease in the number of tumors in the middle and distal parts of the stomach 
(Milne et  al., 2007). Cardia-located gastric cancers may be further divided into two 
separate groups with different aetiologies. One group includes cancers that are 
associated with H. pylori -induced atrophic gastritis and therefore resemble 
adenocarcinomas occurring in the corpus and antrum, whereas the other group is 
associated with gastro-oesophageal reflux-disease and is thus more similar to the 
oesophageal adenocarcinomas (Derakhshan et al., 2008).   
 
Figure  2. Diagram of the stomach (modified from http://www.kliniken.de/images/2/ 
2f/Stomach2.gif). 
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5.1.3 Diagnosis and therapy 
The early stages of gastric cancer are asymptomatic, and most cancers are therefore 
not detected until an advanced stage, when curative options no longer exist 
(Hamilton and Aaltonen, 2000). The 5-year survival rate for patients diagnosed in the 
early stages is 95%, while for those in the advanced stages it is only 10-30% (Keller et 
al., 2005).  The  overall  5-year  survival  rate  in  Finland  between  2003  and  2005  was  
24% for males and 26% for females (Finnish Cancer Registry). 
Diagnosis of gastric carcinomas is based almost solely on endoscopy and 
histological examination of tissue samples (Kokkola et al., 2005). Endoscopy is the 
most sensitive and specific method used in gastric cancer diagnosis, enabling the 
detection of even small changes in the mucosal surfaces of the stomach. In Japan, 
radiology is used for mass screening purposes, followed by endoscopy when needed 
(Hamilton and Aaltonen, 2000). Before treatment, tumor staging is performed with 
an endoscopic ultrasound or computerized tomography to estimate the extent of the 
primary tumor and to detect distant lymph node and liver metastases (Fuchs and 
Mayer, 1995; Hamilton and Aaltonen, 2000; Kokkola et al., 2005). Gastric carcinomas 
may spread by direct extension, metastasis, or peritoneal dissemination. In direct 
extension, the cancer spreads through the stomach wall to the perigastric tissue and 
occasionally invades adjacent structures, such as the liver, pancreas, or colon. Diffuse 
tumors metastasize preferentially through direct extension to duodenum, but the 
frequency of lymphatic, serosal, and vascular invasion is also high. Intestinal tumors 
metastasize preferentially to the liver through hematogenous dissemination, but 
pulmonary metastases are also encountered (Fuchs and Mayer, 1995; Hamilton and 
Aaltonen, 2000).  
 The  only  curative  treatment  option  for  gastric  cancer  is  the  removal  of  the  
tumor tissue either surgically or endoscopically (Kokkola et al., 2005). Neoadjuvant 
and adjuvant treatment, including radiotherapy, chemotherapy, and 
chemoradiotherapy, has also been used in combination with surgery. Radiotherapy is 
best suited for palliative treatment of advanced disease, whereas chemotherapy is 
usually administered following surgery to eliminate residual disease and to improve 
survival. Unfortunately, gastric cancers are relatively resistant to both radiotherapy 
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and chemotherapy, and the benefit of these treatments remains unclear (Ng et al., 
2007a). 
 
5.2 Genomic  alterations  in cancer 
5.2.1 Types of genomic alterations in cancer  
The development of cancer is a multistep process that includes the accumulation of 
both genomic and epigenetic changes, which eventually lead to uncontrolled cell 
proliferation, altered cell morphology and formation of a tumor. The genomic 
alterations include numerical (copy number gains and losses) and structural 
(inversions, point mutations, translocations) chromosomal alterations (Table 1) 
(Rabbits, 1994; Rowley, 1998; Weinberg, 2007).  
 The structural chromosomal changes may be either balanced (reciprocal) or 
unbalanced (nonreciprocal). In a balanced alteration, an even exchange of 
chromosomal parts occurs between nonhomologous chromosomes and no genetic 
material is lost or gained, whereas in unbalanced translocations the exchange is 
unequal, resulting in extra or missing copies of genes and chromosome regions 
(Albertson et al., 2003; Fröhling et al., 2008). Balanced alterations are further divided 
into those that lead to a formation of chimeric fusion genes, and those that lead to 
aberrant gene regulatory elements to be placed in juxtaposition to a structurally 
intact gene (Fröhling et al., 2008).  
 Epigenetic changes do not alter the DNA sequence itself, but rather modify 
the transcription of DNA through DNA methylation or modification of chromatin 
components, such as histones (Baylin and Ohm, 2006; Jones and Baylin, 2007). 
Genomic and epigenetic changes induce gene expression alterations that give the 
host cells a selective growth advantage and result in uncontrolled tumor growth. In 
this review, we will mainly focus on two types of cancer-related genomic alterations: 
the gene copy number and gene expression alterations.  
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Table 1. Types of genomic alterations in cancer.  
Chromomal 
alterations 
Description Role in cancer Examples of 
affected 
genes 
References 
Chromosomal 
gain 
DNA copy number 
increase 
Activation of 
oncogenes 
MYC, ERRB2 Koo et al., 2000; 
Varis et al., 
2004 
Chromosomal 
loss 
DNA copy number 
decrease 
Inactivation of tumor 
suppressor genes 
DCC, BCL2 Uchino et al., 
1992; Ayhan et 
al., 1994 
Inversion DNA is reversed and re-
inserted into the 
chromosome 
Creation of chimeric 
fusion genes and 
aberrantly regulated 
structurally intact 
genes 
RET-PTC,  
EML4–ALK  
Pierotti et al., 
1992; Soda et 
al., 2007  
Point 
mutation 
(insertion, 
deletion, 
substitution) 
Addition or removal of a 
nucleotide, replacement 
of one nucleotide by 
another 
Activation of 
oncogenes and 
inactivation of tumor 
suppressor genes 
APC, CDH1 Nakatsuru et al., 
1992; Grady et 
al., 2000 
Translocation Re-arrangement of 
parts between 
nonhomologous 
chromosomes  
Creation of chimeric 
fusion genes and 
aberrantly regulated 
structurally intact 
genes 
BCR-ABL,  
MYC-IGHG1 
Nowell and 
Hungerford, 
1960; Taub et 
al., 1982 
Epigenetic 
alterations 
Description Role in cancer Examples of 
affected 
genes 
References 
DNA 
methylation 
 
Addition of a methyl 
group to DNA 
Inactivation of tumor 
suppressor genes 
CDH1, MLH1 Tamura et al., 
2000; Baylin 
and Ohm, 2006 
Histone 
modification 
 
Acetylation and 
methylation of histones 
Regulation of 
transcription 
HOXB13, 
p16, MLH1 
Meng et al., 
2007; Ren et al., 
2009  
Nucleosome 
remodeling 
ATP-dependent 
alterations in DNA-
histone interactions and 
DNA accessibility 
Regulation of 
transcription 
BRG1 Wong et al., 
2000 
 
5.2.2 Chromosomal aberrations 
Each normal human cell contains 46 chromosomes, including 22 pairs of autosomal 
chromosomes and a pair  of  sex chromosomes (either XX or  XY).  Each chromosome 
pair contains two homologous copies of the chromosome, one from each parent. 
Cancer cells are, however, often chaotic in terms of chromosomal integrity and 
chromosomes that structurally resemble normal chromosomes may contain extra 
copies of chromosomal regions or entire chromosomes (Weinberg, 2007). This leads 
to an increased copy number of genes located in these regions, i.e. gene 
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amplification.  In tumors, gene amplifications tend to occur in genes that favor cell 
proliferation (oncogenes). However, only a small portion of the amplified genes play 
a direct role in tumorigenesis. High-level amplification can often be manifested by 
formation of either double minutes or homogenously staining regions. Double 
minutes are generated when a part of the chromosome is broken off and replicated 
as an autonomous, extrachromosomal entity. This results in a copy number increase 
and in the appearance of subchromosomal fragments called double minutes. 
Homogenously staining regions are produced when a small segment of the 
chromosome is copied multiple times. The resulting extra copies fuse together in a 
head-to-tail orientation within the same chromosomal segment and form 
homogenously staining regions (Weinberg, 2007). Certain chromosomal regions or 
entire chromosomes may also be lost during carcinogenesis in tumors. This leads to a 
decreased copy number of the genes located in these regions. In contrast to 
amplifications, gene copy number losses tend to occur in genes that inhibit cell 
proliferation (tumor suppressor genes) (Weinberg, 2007), but chromosomal 
deletions also include genes that do not directly contribute to tumorigenesis.  
In addition to numerical chromosomal alterations, chromosomes may also 
undergo structural alterations such as translocations, inversions, and insertions. 
These chromosomal rearrangements occur mainly in the hematological cancers and 
tumors of mesenchymal origin (Rabbits, 1994; Rowley, 1998). However, some recent 
studies  have  shown  that  they  also  play  a  role  in  certain  epithelial  tumors  such  as  
prostate cancer and non-small-cell lung cancer (Tomlins et al., 2005; Iljin et al., 2006; 
Meyerson, 2007; Soda et al., 2007).  
 
5.2.3 Gene expression alterations 
The number of protein coding genes in the human genome is currently estimated at 
23,500 (www.ensembl.org, accessed 26.10.2009). DNA molecules are copied into 
RNA  in  a  process  called  transcription,  and  a  gene  that  is  being  transcribed  is  thus  
actively expressed. RNA molecules are then translated into proteins by ribosomes. 
Depending on the cell type, environmental conditions, and the stage of 
development, different genes are actively transcribed and translated into proteins. 
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Activation and repression of specific genes are required for the adjustment of normal 
cells to different environmental conditions, for the differentiation of cells into 
specific tissues, but also for the dedifferentiation of normal cells into cancerous cells 
(Weinberg et al., 2007).  
One gene may encode for a number of different proteins. This is due to 
alternative splicing of mRNA as well as posttranslational modifications such as 
phosphorylation and acetylation (Witze et al., 2007). In normal cells, gene expression 
is controlled both transcriptionally and epigenetically. Transcriptional control is 
coordinated by transcription factors, proteins that bind to the gene’s promoter 
region and activate or repress the expression of the gene (Weinberg, 2007). 
Epigenetic control refers to changes in gene expression not associated by changes in 
the DNA sequence, such as DNA methylation or chromatin modifications (Baylin and 
Ohm, 2006; Jones and Baylin, 2007).  
Neoplasms arise when a normal cell escapes the control mechanisms for 
gene expression and cell growth. Cancer cells are characterized by six different 
hallmarks: self-sufficiency in growth signals, insensitivity to anti-growth signals, 
resistance to apoptosis, invasion to the surrounding tissues and formation of 
metastases, sustained angiogenesis, and limitless replicative potential (Hanahan and 
Weinberg, 2000). One of the most important gene expression control mechanisms 
for cancer cell survival and cancer progression is a change in the gene copy number 
(Pollack  et  al., 1999; Hyman et al., 2002; Wolf et al., 2004; Järvinen et al., 2006; 
Järvinen et al., 2008). Such copy number alterations often involve a large group of 
genes located close to one another in the same chromosome. For example, in gastric 
cancers, the frequently amplified 17q12-q21 region contains several amplified genes, 
including ERBB2, GRB7, JUP, PERLD1, PNMT, PPP1R1B, STARD3, and TOP2A (Varis et 
al., 2004; Maqani et al., 2006). However, only a minority of these genes are likely to 
be the true driver genes, hence contributing to tumorigenesis, while others (the 
passenger genes) may be amplified simply because of their chromosomal proximity 
to the amplification target gene (Leary et al., 2008; Torkamani et al., 2008). Driver 
genes activate the neoplastic process, and mutations in these genes contribute to 
the transformation of a normal cell to a proliferating cancer cell. One approach for 
distinguishing such driver genes from the passenger mutations is to integrate gene 
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copy number and expression information, thus pinpointing genes whose 
transcriptional activation or repression is associated with a copy number change in a 
cancer cell. Functional studies of such genes, e.g. using cultured cells, may be used to 
further validate the potential role of such genes as the true drivers of carcinogenesis.  
 
5.2.4 Oncogenes and tumor suppressor genes 
Oncogenes are involved in tumor formation when they are activated since they 
encode proteins, such as transcription factors, growth factors, growth factor 
receptors, signal transducers, chromatin remodelers, and apoptosis regulators, 
which  induce  cell  proliferation  (Weinberg,  2007;  Croce,  2008).  Oncogenes  may  be  
activated through chromosomal rearrangements (e.g. translocations and inversions), 
point mutations, or gene amplifications (Croce, 2008). Even though activated 
oncogenes are often found in cancer cells, they are rarely or never inherited 
(Knudson, 1985).  
Tumor suppressor genes are involved in the tumor formation when they are 
inactivated or lost. This is because, when active, these genes inhibit cell proliferation 
and suppress tumor formation. Inactivating somatic mutations in tumor suppressor 
genes occur frequently during tumorigenesis (Yeo, 1999). Inactivation of one allele, 
however, is not sufficient for the tumor formation. This is because tumor suppressor 
genes are recessive, and therefore cells that contain one normal and one mutated 
allele and are thus heterozygous, still behave normally. In 1971, Knudson proposed a 
two-hit mechanism in which both alleles need to be inactivated to promote 
malignant growth (Knudson, 1971). In familial cancers, an inherited germline 
mutation represents the first hit, which is followed by a somatic mutation. In 
sporadic  cancers,  both  mutations  are  somatic.  In  addition  to  mutations,  tumor  
suppressor genes may become inactivated by methylation or loss of heterozygosity 
(LOH) (Knudson, 1993; Weinberg, 2007). LOH may occur through a loss of a 
chromosomal region, mitotic recombination, inappropriate chromosomal 
segregation, or gene conversion (Weinberg, 2007). Tumor suppressor functions can 
be separated into three major categories: gatekeepers, caretakers, and landscapers 
(Kinzler and Vogelstein, 1997; Kinzler and Vogelstein 1998; Weinberg, 2007). 
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Gatekeepers, such as RB1 and TP53, directly control cell growth, cell differentiation, 
and cell death, whereas caretakers, such as BRCA1 and BRCA2, are the guardians of 
the cellular genomes. Landscapers mainly affect the tumor microenvironment.  
Both oncogenes and tumor suppressor genes are required for normal cell 
proliferation and differentiation, but their aberrant expression leads to abnormal cell 
proliferation and potentially malignant growth. Typically, a single genetic event is not 
sufficient  for  tumor  formation,  but  rather,  multiple  genetic  alterations  involving  a  
number of oncogenes and tumor suppressor genes are required for a normal cell to 
transform into an invasive cancer cell.   
 
5.3 Microarrays in profiling the cancer genome 
Microarrays  can  be  used  for  the  measurement  of  relative  levels  of  basically  any  
biomolecule,  but  typically  DNA,  RNA,  or  proteins,  in  a  cell.  Microarrays  have  a  
number of different applications. Numeric chromosomal changes may be measured 
using comparative genomic hybridization (CGH) arrays or single nucleotide 
polymorphism (SNP) oligonucleotide arrays, whereas with gene expression arrays 
one is able to measure the transcriptional activity of genes. Each microarray contains 
a short stretch of DNA fragments printed or in situ-synthesized on a solid support. 
These DNA fragments (i.e. target DNA) may be complementary DNA (cDNA), 
bacterial artificial chromosomes (BAC) or they may be synthetically produced 
oligonucleotides of varying lengths, usually 25-80 nucleotides long (Solinas-Toldo et 
al., 1997; Pinkel et al., 1998; Pollack et al., 1999).  
 
5.3.1 Comparative genomic hybridization 
Comparative genomic hybridization (CGH) is a method that enables genome-wide 
screening of numeric chromosomal alterations, i.e. detection of gains and losses of 
specific DNA sequences. The flowchart of this method is depicted in Figure 3. CGH, 
first described by Kallioniemi and colleagues in 1992, is based on a principle where 
equal amounts of test (e.g. cancer) and reference (e.g. normal) sample DNAs are 
labeled with two different fluorochromes and hybridized onto a glass slide 
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containing the target DNA. The ratio of the hybridization signals between the 
fluorochromes is then used to determine the relative differences of genetic material 
between the two samples. The advantage of this method is the simultaneous 
screening of copy number alterations throughout the genome and its improved 
sensitivity compared with earlier methods for DNA copy number detection such as 
fluorescent in situ hybridization (FISH).  
Originally, the target DNA placed on the glass slide contained metaphase 
chromosomes extracted from normal cells (chromosomal CGH, cCGH) (Kallioniemi et 
al., 1992). In the arrayCGH (aCGH), the metaphase chromosomes have been replaced 
with arrays of DNA clones (e.g. cDNAs and oligonucleotides) spanning the entire 
genome, which has improved the sensitivity of these arrays tremendously (Solinas-
Toldo et al., 1997; Pinkel et al., 1998; Pollack et al., 1999). The most recent addition 
to the aCGH family is the SNP oligonucleotide array (Bignell et al. 2004; Zhao et al., 
2004), which enables simultaneous detection of copy number changes and single 
nucleotide polymorphisms (SNPs).  
 
Figure 3. Flowchart of arrayCGH analysis. 
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Cyanine 3 (Cy3) and Cyanine 5 (Cy5) are the mostly used fluorochromes in the 
labeling procedure (Cowell and Hawthorn, 2007). For example, if the tumor DNA is 
labeled with Cy5 (producing a red signal on the array) and the reference DNA with 
Cy3 (producing a green signal on the array), copy number loss in the tumor sample 
results in an increased green signal, whereas copy number gain results in an 
increased red signal. Similar copy number levels in the tumor and reference samples 
are indicated by a yellow spot on the array.  The reference DNA is usually derived 
from normal diploid cells (e.g. DNA extracted from lymphocytes from several healthy 
blood donors) (Cowell and Hawthorn, 2007).   
The advantage of aCGH is that genome-wide information of numeric 
chromosomal alterations can be obtained effectively in a high resolution and the 
amount of DNA required for the analysis is relatively low. However, aCGH measures 
changes  only  in  the  DNA  content,  whereas  balanced  structural  chromosomal  
alterations are left undetected. Also, heterogeneity of the tumor samples affects the 
analysis, leading to an underestimation of actual copy number changes in the tumor 
sample (Cowell and Hawthorn, 2007). The tumor content in the sample therefore  
needs to be at least 50% (preferably higher) in order for tumor-specific copy number 
changes to be detected (Pollack et al., 1999). To reduce the effect of sample 
heterogeneity, laser capture microdissection (Emmert-Buck et al., 1996) can be used, 
which enables the collection of selected cell populations from a heterogeneous 
tissue.  
 CGH arrays have been deployed in characterizing many different types of 
human cancers, and specific copy number changes have been correlated with 
different tumor subtypes,  tumor stage,  metastasis,  survival,  recurrence,  and age of  
the patient (Wu et al., 2001; Hyman et al., 2002; Weiss et al., 2004; Wolf et al., 2004; 
Yang et al., 2005; Buffart et al., 2006; Järvinen et al., 2006; Kang et al., 2006; Furuya 
et al., 2008).  
 
5.3.2 Gene expression arrays 
Gene expression arrays were first described by Schena and colleagues in 1995, and 
they are used to measure mRNA expression levels of the genes on a genome-wide 
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scale.  The general principle is similar to that described for CGH arrays in Figure 3. 
However,  since  RNA  is  used  as  a  source  material  instead  of  DNA,  the  sample  
preparation is somewhat different.  Since RNA is easily degradable, it is first reverse-
transcribed into cDNA and simultaneously labeled with fluorescent dyes (Schena et 
al., 1995). Intact, good-quality RNA is a prerequisite for a successful gene expression 
microarray experiment.  
There are basically two types of gene expression arrays: one-color and two-
color arrays. On two-color arrays, the test sample and the reference sample are 
simultaneously hybridized onto the glass slide. Normal tissue or a universal reference 
containing, for example, a pool of tumor cell lines may be used as reference when 
the aim is to identify cancer-related changes in gene expression. On one-color arrays, 
the test and reference sample may be hybridized on different chips, and the 
comparison of different samples is carried out computationally (Cowell and 
Hawthorn, 2007). The advantage of gene expression microarray analysis is a 
genome-wide screening of expression alterations in a single experiment. Typically, 
the probes on the gene expression arrays are designed for the 3’ end of the 
transcript. However, probes can also be designed to specifically map each exon of 
the transcript, enabling the measurement of alternatively spliced transcripts (Clark et 
al., 2007).  
Microarrays have been used in nearly all fields of biomedical research for 
identifying the molecular mechanisms of diseases and for estimating the effects of 
drug treatments (Golub et al., 1999; Gordon et al. 2002; Pomeroy et al., 2002). 
Several recent studies have also used gene expression profiles in the molecular 
classification of tumors (Alizadeh et al., 2000; Sorlie et al., 2001) and in predicting 
the clinical outcome of cancers (Rosenwald et al., 2002; Van’t Veer et al., 2002; 
Vecchi et al., 2007).  
 
5.3.3 Tissue microarrays 
Tissue microarray (TMA) technology, first described by Kononen and colleagues in 
1998, enables as many as 1000 cylindrical tissue biopsies to be surveyed 
simultaneously on a single microarray. The tissue biopsies are arrayed at a high 
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density  on  a  TMA  block,  and  up  to  300  consecutive  sections  can  be  cut  from  each  
block and probed for DNA-, RNA- or protein-level alterations (Kononen et al., 1998; 
Kallioniemi et al., 2001).  The advantage of TMA technology is that different DNA, 
RNA, and protein targets may be measured consecutively from practically identical 
regions  of  the  tumors  (Kononen  et  al., 1998). This TMA-based detection can be 
performed with the fluorescent in situ hybridization (FISH), in situ hybridization (ISH), 
or immunohistochemistry (IHC) techniques. TMAs have been used in several studies 
to assess the significance of molecular alterations in different types of cancers 
(Bubendorf  et  al., 1999;  Bärlund  et  al., 2000; Richter et al., 2000; Cao et al., 2007; 
Erbersdobler et al., 2009; Takikita et al., 2009), including gastric cancers (Wang et al., 
2009).  
 
5.4 Gene copy number and expression alterations in gastric carcinoma 
Several different types of molecular alterations occur during gastric carcinogenesis, 
including gene copy number and expression alterations, point mutations, and 
microsatellite instability (Grady et al., 2000; Keller et al., 2005; Hamilton and 
Meltzer, 2006; Tsukamoto et al., 2008). Gastric cancers are complex in terms of their 
genomic profiles, and accumulation of a number of genetic alterations is needed for 
neoplastic growth. Different genomic alterations have been suggested for different 
histological  types of  gastric  cancer (Kokkola et  al., 1997; Keller et al., 2005) and for 
gastric tumors with different invasive and metastatic potentials (Hasegawa et al., 
2002).  Here,  we  will  mainly  focus  on  two  types  of  gastric  cancer-related  genomic  
alterations: the gene copy number and expression alterations.  
 
5.4.1 Gene copy number alterations 
Chromosomal instability represents a key step in gastric carcinogenesis, with most of 
the primary tumors exhibiting abnormalities in their cellular DNA content (Grabsch 
et al., 2004). Various studies have identified several chromosomal regions with DNA 
copy number alterations in gastric carcinoma. Table 2 summarizes the most frequent 
chromosomal aberrations identified in 12 recent gastric cancer CGH studies. The 
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majority  of  these  studies  report  copy  number  gains  at  8q,  17q,  and  20q  and  copy  
number losses at 4q, 5q, and 18q. Other commonly reported copy number 
alterations include gains at 1q, 7p, 8p, 13q, 19q, and 20p and losses at 1p, 9p, 16q, 
and 21q.  
 
Table 2. Chromosomal regions with frequent copy number changes in gastric carcinomas.  
Study Gain/amplification Loss/deletion Samples Method 
Kokkola et al., 
1997 
8q, 17q, 20q 18q, 4q 35 primary tumors: 
22 intestinal 
13 diffuse 
cCGH 
Sakakura et al., 
1999 
1p, 8p, 8q, 11q, 16p, 
20p, 20q, Xp 
1p, 3p, 5q, 6q, 9p, 
16q, 17p, 18q, 19 
58 primary tumors cCGH 
Wu et al., 
2001 
6q, 7p, 8q, 11q, 
13q,17q, 20q 
1p, 3p, 4q, 5q, 16q, 
19p 
53 primary tumors: 
28 intestinal 
25 diffuse 
cCGH 
Tay et al., 
2003 
7p, 8q, 11p, 13q, 16p, 
17q, 20q, 20p 
4q, 5q, 18q 60 primary tumors: 
41 intestinal 
17 diffuse 
2 mixed 
cCGH 
Weiss et al., 
2004 
1q, 7p, 8q, 8p, 20q 5q, 9p, 13q, 16q, 
17p, 18q, 19p, 21q 
35 primary tumors: 
25 intestinal 
5 diffuse 
5 mixed 
aCGH 
Gorringe et al., 
2005 
1q, 6p, 17, 19q 1p, 4q, 5q, 15q, 
16q, 21q 
20 primary tumors: 
13 intestinal 
4 diffuse 
3 mixed 
aCGH 
Vauhkonen et al., 
2006 
1q, 8, 10p, 20q 1p, 5p 7 primary tumors: 
7 intestinal 
aCGH 
Kang et al., 
2006 
1p, 5p, 7q, 8q, 11p, 
16p, 20p, 20q 
1p, 2q, 4q, 5q, 7q, 
9p, 14q, 18q 
28 primary tumors aCGH 
Vauhkonen et al., 
2007 
8q, 13q, 17q, 19q, 20q 4q, 5q, 9p, 18q, 
21q 
15 primary tumors: 
12 intestinal 
3 diffuse 
aCGH 
Yang et al., 
2007a 
 
8, 13, 20, X 4, 6, 18, Y 30 primary tumors aCGH 
Tsukamoto et al.,  
2008 
1q, 2q, 3q, 5p, 6q,  
7p, 8p, 8q, 11q, 13q, 
17q, 19q, 20p, 20q 
3p, 4p, 4q, 5q, 9p, 
10q, 12q, 16q, 17p, 
18q, 21q 
30 primary tumors: 
16 intestinal 
14 diffuse 
aCGH 
Furuya et al., 
2008 
8q, 20q 1p, 4q, 14q, 22q 83 primary tumors: 
41 intestinal 
42 diffuse 
aCGH 
cCGH, chromosomal CGH; aCGH, array CGH 
 
 Some of the copy number gains and losses have been correlated with 
different clinical features of gastric cancer, such as histological subtype. Compared 
with  the  diffuse  subtype,  intestinal  gastric  cancers  show  a  higher  number  of  copy  
number gains at 8q, 17q, and 20q as well as more losses at 3p and 5q (Kokkola et al., 
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1997; Wu et al., 2001).  On  the  other  hand,  diffuse-type  gastric  cancers  are  more  
likely to show copy number gains at 12q and 13q and losses at 4q, 15q, 16q, and 17p 
(Wu et al., 2001; Weiss et al., 2004; Tsukamoto et al., 2008), suggesting that these 
two subtypes represent distinct disease entities with regard to their molecular 
genetic alterations. Specific copy number alterations have also been correlated with 
gastric cancer stage, metastases, survival, recurrence, growth site, and patient age 
(Wu et al., 2001; Weiss et al., 2004; Yang et al., 2005; Buffart et al., 2006; Kang et al., 
2006; Furuya et al., 2008). Moreover, these studies have shown that DNA aneuploidy 
is often greater with advanced disease state and poorer prognosis.  
 
5.4.2 Gene expression alterations  
Microarray-based gene expression profiling of gastric cancer has enabled a genome-
wide assessment of the transcriptional activity of individual genes in gastric cancer 
cells (Hasegawa et al., 2002; Hippo et al., 2002; Boussioutas et al., 2003; Chen et al., 
2003; Tay et al., 2003; Jinawath et al., 2004; Kim et al., 2007; Vecchi et al., 2007; 
Yang et al., 2007a; Yang et al., 2007c; Takeno et al., 2008; Tsukamoto et al., 2008). 
Specific gene expression patterns have been correlated with histology (Hippo et al., 
2002; Boussioutas et al., 2003; Chen et al., 2003;  Kim  et  al., 2003; Jinawath et al., 
2004),  invasiveness (Hasegawa et al., 2002; Hippo et al., 2002), and survival (Chen et 
al., 2003; Tay et al., 2003; Vecchi et al., 2007).  So  far,  only  a  few  studies  have  
integrated changes in the gene expression with simultaneous gene copy number 
alterations in gastric cancers (Yang et al., 2007a; Tsukamoto et al., 2008). 
 
5.4.3 Genetic progression model for gastric cancer 
The molecular mechanisms leading to gastric cancer are complex and involve an 
accumulation of a number of genetic alterations. Furthermore, the genetic 
alterations  between  the  two  histological  subtypes,  intestinal  and  diffuse,  seem  to  
differ (Keller et al., 2005;  Hamilton  and  Meltzer,  2006).  The  majority  of  gastric  
carcinomas  develop  as  a  result  of  a  combination  of  genetic,  epigenetic,  and  
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environmental factors. The most common somatic alterations behind gastric 
carcinogenesis are summarized in Figure 4.  
Microsatellite instability (MSI) has been detected in both diffuse- and 
intestinal-type gastric tumors, but it is more common in the latter (Keller et al., 2005; 
Hamilton and Meltzer, 2006). MSI refers to a situation in cancer cells where sections 
of DNA, called microsatellites, become unstable. MSI is associated with a defect in 
the cell’s ability to repair mistakes that occur during DNA replication (Halling et al., 
1999; Hamilton and Meltzer, 2006). In healthy individuals, during DNA replication, 
mismatch repair genes MLH1 and MLH2 proofread DNA and repair spontaneous 
replication errors. Inactivation or loss of these genes in gastric cancer leads to MSI 
and formation of truncated proteins (Halling et al., 1999; Lee et al., 2004). Another 
predisposing factor for both histological subtypes is Helicobacter pylori infection 
(Asaka et al., 1997; Hamilton and Meltzer, 2006).  
 
 
 
Figure 4. Genetic alterations in gastric cancer (Keller et al., 2005).  
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5.4.3.1 Intestinal gastric cancer 
Inactivation of p53, APC, and DCC genes has been reported in intestinal gastric 
cancer (Figure 4) (Keller et al., 2005). p53 is a tumor suppressor gene that regulates 
DNA repair. Cells lacking p53 are deficient in inducing apoptosis and controlling 
tumor growth. p53 is  mutated  in  a  large  portion  of  the  premalignant  stages  of  
intestinal gastric cancers and in 30-50% of all gastric carcinomas (Sakurai et al., 1995; 
Feng  et  al., 2002; Keller et al., 2005; Hamilton and Meltzer, 2006). Another well-
known tumor suppressor gene, APC, is mutated in up to 60% of intestinal-type 
gastric cancers (Nakatsuru et al., 1992). In normal cells, APC binds to β-catenin, 
which results in the phosphorylation of β-catenin and the negative regulation of the 
Wnt signaling pathway. This blocks cell cycle progression. Mutations in APC and/or β-
catenin prevent APC from binding to β-catenin, thus leading to an abnormal cell 
proliferation (Senda et al., 2005). DCC is located in the 18q chromosomal region, 
which is frequently deleted in gastric cancers (Table 2). This gene is involved in cell 
migration,  cell  cycle  arrest,  and  apoptosis  (Uchino  et  al.,  1992;  Chen  et  al., 1999; 
Cooper et al., 1999). DCC encodes for a protein belonging to the immunoglobulin 
superfamily and has been suggested to induce apoptosis by activating caspase 3 
(Turley et al., 1995; Chen et al., 1998; Mehlen et al., 1998).  
Other tumor suppressor genes inactivated in intestinal gastric cancer include 
p27, BCL2, nm23, and CDH1 (encodes for E-cadherin) (Figure 4). The role of CDH1 in 
the hereditary diffuse gastric cancer was discussed earlier (see sections 5.1.1 and 
5.1.2.1), but it also has a tumor suppressor role in intestinal-type gastric tumors 
(Keller et al., 2005).  However, in contrast to the diffuse tumors, in intestinal gastric 
tumors CDH1 mutations are rare, and instead CDH1 is inactivated through promoter 
hypermethylation or through direct transcriptional inactivation by repressor 
molecules (Batlle et al., 2000; Tamura et al., 2000).   
In addition to the tumor suppressor genes mentioned above, intestinal 
gastric cancer progression also involves activation of many oncogenes such as K-ras, 
Cyclin E, c-met, and ERBB2 (Figure 4). K-ras belongs to the Ras-oncogene family and 
encodes for a protein involved in many signal transduction pathways (Hamilton and 
Meltzer, 2006). Cyclin E, like other cyclins, regulates CDK kinases and plays a role in 
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the initiation of DNA replication, in the control of genomic stability, and in the 
centrosome cycle (Möröy and Geisen, 2004). The oncogene c-met encodes  for  a  
receptor tyrosine kinase that regulates signaling pathways important to cell growth, 
differentiation, and proliferation (Drebber et al., 2008). Amplification and 
overexpression of c-met has been reported in gastric cancers and many other 
carcinomas (Maggiora et al., 2003; Inoue et al., 2004; Tang et al., 2004; Lutterbach et 
al., 2007). ERBB2 (also known as HER2, human epithelial growth factor receptor 2) is 
amplified and overexpressed in a number of solid tumors, including gastric tumors 
(Menard et al., 2001; Takehana et al., 2002; Varis et al., 2004; Park et al., 2006). In 
gastric cancers, elevated ERBB2 expression is significantly higher in the intestinal 
subtype than in the diffuse subtype (Garcia et al., 2003), and its overexpression has 
been associated with poorer survival (Vizoso et al., 2004).  Clear  evidence of  ERBB2 
involvement in gastric cancer was established when trastuzumab (ERBB2 tyrosine 
kinase domain binding monoclonal antibody) treatment was shown to inhibit tumor 
growth in gastric cancer cell lines and in one patient with ERBB2 amplification and 
overexpression (Gong et al., 2004; Rebischung et al., 2005).  
 
5.4.3.2 Diffuse gastric cancer 
The pathogenesis of poorly differentiated diffuse-type gastric tumors is less well-
known. Inactivating mutations of the tumor suppressor gene E-cadherin are 
detected in 50% of the sporadic diffuse gastric tumors (Becker et al., 1994), and the 
role of E-cadherin in diffuse-type tumors can be explained by its ability to mediate 
cell-cell interactions and establish cell polarity. A decrease in its expression allows 
the cancer cells to dissociate from their matrix, which promotes migration and tissue 
invasion of cancer cells (Hamilton and Meltzer, 2006). As in intestinal gastric tumors, 
p53 and nm23 are involved in diffuse gastric carcinogenesis, although mutations in 
these genes occur less frequently than in intestinal-type tumors (Figure 4).  
 Oncogenes, such as cyclin E1, c-met, and CD44, involved in diffuse-type 
tumorigenesis are also altered in intestinal-type gastric tumors, but amplification and 
overexpression of Twist1, CDH2 (encodes for N-cadherin), and K-sam are more 
characteristic of diffuse-type tumors (Figure 4) (Keller et al., 2005; Hamilton and 
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Meltzer, 2006). Twist is a transcription factor that promotes gastric cancer cell 
invasion through downregulation of E-cadherin and upregulation of N-cadherin (Yang 
et al., 2007b). A switch from E- to N-cadherin is an important step in the epithelial-
mesenchymal transition (Cavallaro et al., 2002), and unlike E-cadherin, N-cadherin 
promotes cell motility and invasion, and its overexpression leads to higher 
metastatic potential of cancer cells (Rosivatz et al., 2004; Grinberg-Rashi et al., 
2009). K-sam (also known as FGFR2) belongs to the fibroblast growth factor receptor 
family and by interacting with the fibroblast growth factors it influences many 
cellular processes, including cell growth, differentiation, migration, and survival. K-
sam is  often  amplified  and  overexpressed  in  diffuse  gastric  tumors  (Hattori  et  al., 
1996; Hara et al., 1998; Jang et al., 2001). 
  
5.4.3.3 Novel gastric cancer target genes 
Genome-wide microarray analyses have identified a number of genes that are 
suggested to play a role in gastric carcinogenesis (Wu et al., 2001; Hasegawa et al., 
2002; Hippo et al., 2002; Boussioutas et al., 2003; Chen et al., 2003; Tay et al., 2003; 
Jinawath et al., 2004; Weiss et al., 2004; Yang et al., 2005; Buffart et al., 2006; Kang 
et al., 2006; Kim et al., 2007, Vecchi et al., 2007; Yang et al., 2007a; Yang et al., 
2007c; Furuya et al., 2008; Takeno et al., 2008; Tsukamoto et al., 2008). Common 
target genes identified in a majority of these studies include genes located in the 
17q12-q21 amplicon, such as ERBB2, GRB7, PPP1R1B, PPARBP, and STARD3, as well 
as some other known cancer-related genes such as EGFR and HRAS. These studies 
have also identified several novel gastric cancer-associated genes. However, the 
clinical role of these potential gastric cancer target genes needs to be further 
validated.  
To highlight genes potential as biomarkers or clinical targets in gastric cancer, a 
systematic high-resolution array-based survey of copy number and gene expression 
levels in gastric cancer tissues and cell lines was carried out in Studies I and II. 
Furthermore, a comparative analysis of Finnish and Japanese gastric tumors was 
performed  in  Study  III  to  identify  a  potential  set  of  common  gastric  cancer  target  
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genes that show up- or downregulation irrespective of the tissue of origin (Finnish vs. 
Japanese) or the used microarray format.  
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6 AIMS OF THE STUDY 
 
The aims of the study were the following:  
 
1. To map gene copy number alterations in primary gastric carcinomas and in 
gastric cancer cell lines at a high resolution. 
 
2. To integrate gene copy number and expression microarray data to identify 
genes whose expression has altered due to an increased or decreased copy 
number.  
 
3. To compare gene expression changes in Finnish and Japanese primary gastric 
tumors to identify genes commonly altered in gastric cancer.
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7 MATERIALS AND METHODS 
7.1 Clinical gastric tissue samples and gastric cancer cell lines (I-III) 
Clinical gastric cancer samples were prospectively collected from patients who 
underwent gastric surgery or gastroscopy at Helsinki University Central Hospital or 
Sapporo  University  Hospital  between  1999  and  2007.  Informed  consent  was  
obtained from each participating patient, and patient samples were coded by 
clinicians prior to research to ensure anonymity.  
Gastric  cancer  tissue  samples  were  taken  from  the  primary  tumor  site  and  
normal  gastric  tissue  samples  as  far  away  (>5cm)  from  the  tumor  as  possible.  The  
tumor cell content in the tumor samples was >50%. Tissue sections were 
immediately frozen in liquid nitrogen and stored at -80oC to ensure intact sample 
DNA and RNA. Histology of gastric cancer specimens and tumor cell content were 
evaluated by an experienced pathologist. The histological classification was 
determined  according  to  Laurén’s  classification  (Laurén,  1965)  using  frozen  ice-
section preparations. In Studies I-III, altogether 149 individual gastric tumor tissues, 
43 normal gastric tissues, and 7 gastric cancer cell lines were analyzed (Table 3). The 
82 tissue samples (46 cancerous, 36 normal) included in the qRT-PCR analysis were 
shared between Studies II and III, and 64 (36 cancerous, 28 normal) of these samples 
were also analyzed with the TRAC assay in Study II. In addition, the 46 gastric tissue 
samples hybridized on gene expression arrays in Study I were re-analyzed on a 
genome-wide scale in Study III.  
Two of the seven studied gastric cancer cell lines, AGS and KATOIII, were 
obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and 
the other five cell lines, MKN-1, MKN-7, MKN-28, MKN-45, and TMK-1, were a kind 
gift from Hiroshi Yokozaki, Kobe University Graduate School of Medicine, Kobe, Japan 
(Yokozaki, 2000). AGS cells were grown in Kaighn’s F12 medium (2 mM glutamine, 
10%  FBS,  100  U/ml  penicillin-streptomycin),  KATOIII  cells  in  IMDM  medium  (2  mM  
glutamine, 10% FBS, 100 U/ml penicillin-streptomycin), and all other cell lines in 
RPMI-1640 medium (10% FCS, 2 mM glutamine, 100 U/ml penicillin-streptomycin). 
All cells were grown at 37°C and 5% CO2. 
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Table 3. The number and clinical parameters of gastric samples analyzed in Studies I-III.  
Study Total number 
of samples 
Intestinal/ 
Diffuse GCa 
Normal 
tissues 
GCa cell 
lines 
Males/ 
Females 
Mean 
age (yrs) 
Study I:       
CGH array 46 25/13 8 0 23/23 70 
Expression array 46 25/13 8 0 23/23 70 
Tissue microarray 78 49/29 0 0 46/32 65 
Study II:       
CGH array 20 9/4 0 7 6/7 65 
Expression array 10 3/0 0 7 1/2 62 
TRAC assay 95 40/13 35 7 54/34 68 
qRT-PCR 89 29/16* 36 7 51/31 67 
Study III:       
Expression array 66 27/22* 16 0 35/31 68 
qRT-PCR 82 29/16* 36 0 51/31 67 
GCa, Gastric Cancer; *excluding one sample of unknown histology 
 
7.2 Microarray experiments (I-III) 
7.2.1 Nucleic acid extraction, labeling, and hybridization (I-III) 
DNA  was  extracted  from  tissue  samples  and  cell  lines  using  the  DNeasy  tissue  kit  
(Qiagen Inc., Hilden, Germany) (I, II).  Total RNA was extracted from primary gastric 
tumors and gastric cancer cell lines using the RNeasy midi kit (I-III) (Qiagen) or Trizol 
reagent  (III)  (Invitrogen,  Carlsbad,  CA,  USA).  Prior  to  extraction,  the  samples  were  
homogenized with a mechanical Ultra-Turrax homogenizer (IKA Works, Wilmington, 
NC, USA) (tissues) or a needle and syringe (cell lines). The Biophotometer 
(Eppendorf, Hamburg, Germany) (I) and NanoDrop1000 (Thermo Fisher Scientific, 
Vantaa, Finland) (II, III) were applied to measure nucleic acid concentration and 
quality. The quality of the extracted RNA was also evaluated with gel electrophoresis 
and 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA).  
 Fifty-nine gastric tissues and seven gastric cancer cell lines were investigated 
with aCGH. DNA copy number changes were measured using two different 
commercial Agilent CGH arrays containing either 12,000 cDNA (12K cDNA CGH array) 
(I) or 244,000 oligonucleotide (244K oligo CGH array) (II) probes per array. Sixty-nine 
gastric tissues and seven gastric cancer cell lines were investigated with commercial 
Agilent and Affymetrix gene expression arrays containing either 44,000 
oligonucleotide probes (44K expression array) (Agilent) (I-III) or 54,000 probesets 
(Affymetrix HG-U133-Plus 2.0 array) (III) per array. The labeling and hybridization 
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were performed according to manufacturers’ protocols, which are described in detail 
in the original publications (I-III). 
 
7.2.2 Microarray data analysis (I-III) 
The Agilent microarray slides used in Studies I-III were scanned with a DNA 
Microarray Scanner (Agilent Technologies). In Study I, the fluorescence intensities for 
the  two-color  12K  aCGH  and  44K  expression  arrays  were  measured,  and  the  data  
were quality-filtered and normalized using Feature Extraction (v8.1) and Gene Spring 
(v7.3) softwares (Agilent). To further analyze genome-wide gene copy number 
changes  in  gastric  tumors,  CGH  Explorer  (Lingjaerde  et  al.,  2005)  was  applied.  To  
evaluate whether specific copy number alterations were associated with histology or 
location,  Receiver  Operating  Characteristic  (ROC)  analysis  was  used  (Swets,  1998). 
The  clinical  sample  group  comparisons  were  performed  for  intestinal  (n=25)  vs.  
diffuse (n=13) and antrum- (n=19) vs. corpus-located (n=19) gastric tumors. First, the 
ROC curve was estimated for each gene using class labels (histology or location) and 
the information about the gains and losses. The area under the ROC curve was used 
to measure, which chromosomal alterations were significant as classifying the two 
compared sample groups. Moreover, a forward selection algorithm and a Naïve 
Bayes classifier were applied to identify individual genes, whose copy number 
alterations could classify tumors according to histological subtype or location of the 
tumor. The statistical significance of the identified genes was assessed by comparing 
them with randomly selected variables. The Naïve Bayes classifier was trained 10,000 
times with randomly selected variables.  
In Study II, the fluorescence intensities for the two-color 244K aCGH and 44K 
expression arrays were measured, and the data were quality filtered and normalized 
using the Feature Extraction (v9.5.1.1.) software. Gene copy number changes in 
gastric tumors and gastric cancer cell lines were analyzed using CGH Analytics 
(v3.5.14) software.  
In Study III, the fluorescence intensities of the Affymetrix one-color gene 
expression microarray slides were measured using the GeneArray Scanner and signal 
intensities were converted to numerical data using the GeneChip Operating 
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Software. The genome-wide expression changes were analyzed using Chipster 
software (http://chipster.csc.fi/). Also, the 44K gene expression data produced in 
Study  I,  was  re-analyzed  in  Study  III  on  a  genome-wide  scale  using  Chipster.  To  
delineate which biological processes and molecular functions were overrepresented 
among the genes identified as differentially expressed between the cancerous and 
nonmalignant gastric tissues, a hypergeometric test for gene ontology (GO) 
(www.geneontology.org) was performed. During the gene ontology analysis, the 
differentially expressed genes were grouped into meaningful classes using different 
GO terms belonging to two main categories: biological process and molecular 
function. Results from the Finnish and Japanese datasets were compared to find 
common gene expression alterations.  
Furthermore, in Study III, we obtained a third unrelated data set (Tsukamoto et 
al., 2008), including twenty-four gastric cancer tissues and five normal gastric tissues 
hybridized  on  1-color  Agilent  44K  expression  arrays,  and  this  data  set  was  re-
analyzed with Chipster using the same data analysis parameters, which were applied 
for our own two datasets (Agilent 2-color and Affymetrix 1-color gene expression 
array data). Thus, in Study III, three different types of microarrays (Agilent 1- and 2-
color  and  Affymetrix  1-color  arrays)  as  well  as  three  different  patient  populations  
were included in the analysis in order to find a common set of deregulated genes, 
detectable irrespective of the patient population, used microarray platform, or the 
laboratory performing the microarray hybridizations.  
 
7.2.3 Integration of gene copy number and expression data (I, II) 
In Studies I and II, the data obtained from gene copy number and gene expression 
microarrays were integrated to identify potential gastric cancer target genes in 
which a gain in gene copy number results in overexpression (oncogenes), or in which 
a loss in gene copy number results in underexpression (tumor suppressor genes). 
The  statistical  analysis  of  the  microarray  data  is  described  in  detail  in  the  original  
publications (I, II). Briefly, in Study I, copy number and gene expression data were 
integrated according to a method described by Hautaniemi et al. (2004). CGH and 
gene expression array probes were combined according to their genomic positions 
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and gains and losses were analyzed separately. Using the copy number status (gain 
vs.  normal  copy  number,  loss  vs.  normal  copy  number)  the  samples  were  divided  
into two groups, and the mean gene expression was then calculated for each group. 
Signal-to-noise statistics and random permutations of the label vectors were 
performed to define the statistical significance of the association between gene copy 
number and gene expression alterations. α-values (comparable to p-values) <0.05 
were considered statistically significant. Normal tissues were not included in the 
integration analysis.  
In Study II, the integration analysis was restricted to genes located in the 
recurrent (≥25%) regions of chromosomal aberrations. Using the copy number 
status, the samples were divided into two groups (as in Study I), and the median 
gene  expression  was  calculated  for  each  group.  Genes  with  at  least  a  2-fold  copy  
number associated change (fold change, FC) in their expression were considered to 
have a significant association between copy number and gene expression.  
 
7.3 Validation of microarray results (I-III) 
7.3.1 Immunohistochemistry using tissue microarrays (I) 
In Study I, protein-level expression of ERBB2 (17q21.1) and MUC1 (1q21) was studied 
in 78 gastric cancer tissues, including 49 intestinal and 29 diffuse cancers. The tissue 
samples were taken from three different locations in the stomach: the cardia (n=16), 
corpus (n=30), and antrum (n=30). The location of two samples was unknown. The 
samples in the tissue microarray were independent of the samples used in the 
integrated microarray analysis. The preparation of tissue microarray has been 
documented previously (Varis et al., 2004). Briefly, five micrometer sections were cut 
from the tissue microarray block and the microarray slides were stained with 
hematoxylin to evaluate the histology of the samples. Tissue array slides were then 
pre-treated with Tris-EDTA (pH 9.0) or with citrate (pH 6.0) for 24 min in a 
microwave oven prior to staining with ERBB2 and MUC1 antibodies, respectively. 
TMA slides were stained using a 1:500 dilution of NCL-CBII (c-erbB-2 Oncoprotein) 
and a 1:25 dilution of NCL-MUC-1-CORE (Muc-1 Core Glycoprotein) mouse 
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monoclonal antibodies (Novocastra Laboratories Ltd., Newcastle, UK). 
Immunoreactivity of the gastric cancer samples was scored as negative, weak 
positive, positive, or strong positive (Figure 5). The differences in the frequencies of 
immunopositive samples in the intestinal and diffuse subtypes as well as in samples 
from the distal (antrum) and proximal (corpus and cardia) parts of the stomach were 
determined using a z-test for two proportions. 
 
Figure 5. Scoring of the ERBB2 and MUC1 immunostaining. Examples of gastric cancer tissue 
samples scored as weak positive, positive, and strong positive are shown.  
 
7.3.2 Transcript analysis with aid of affinity capture (TRAC assay) (II) 
In Study II, eleven genes showing increased expression and mapping to the recurrent 
(≥25%) regions of copy number gains were validated using an affinity capture-based 
transcript analysis (TRAC) (PlexPress, Helsinki, Finland) that allows a multiplex 
hybridization of specific fluorophore-labeled probes to their target mRNAs in a 
pooled format. Two micrograms of gastric RNA was hybridized with a pool of gene-
specific detection probes and biotinylated capture probes. RNA-probe complexes 
were then captured on streptavidin-coated magnetic beads, washed, and eluted. The 
level of mRNA expression of each gene was measured by capillary electrophoresis.  
The genes included in the transcript analysis were ENAH (1q42.12), OSMR 
(5p13.1), CYP3A4 (7q21.1), ASAP1 (8q24.1-q24.2), LTB4R (14q11.2-q12), PERLD1 
(17q12), ERBB2 (17q21.1), PNMT (17q21-q22), CEACAM5 (19q13.1-q13.2), PTPRA 
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(20p13), and MMP9 (20q11.2-q13.1), each located in recurrent regions of 
chromosomal gains. The mRNA expression levels of these genes were measured in 
88 gastric tissues (53 cancerous and 35 nonmalignant tissues) and in 7 gastric cancer 
cell lines. Both histological subtypes of gastric cancer were represented (intestinal, 
n=40; diffuse, n=13), and the tissue samples were taken from three different 
locations in the stomach: angulus (n=1), corpus (n=41), and antrum (n=46). 
A nonparametric Mann-Whitney test was applied to measure the statistical 
significance of the differences in the expression levels between nonmalignant (n=35) 
and cancerous (n=60) samples as well as between tumors of different histology and 
TNM stage.  Intestinal-type tumors (n=40) were compared with diffuse-type tumors 
(n=13), T1-T2 tumors (n=12) with T3-T4 tumors (n=34), N0 tumors (n=9) with N1-3 
tumors (n=38), and metastasized tumors (n=11) with nonmetastasized tumors 
(n=36). Moreover, copy number data (obtained in Studies I and II) were available for 
43 of the 60 cancer samples. Therefore, the statistical significance of the copy 
number-associated gene expression changes, as measured by the TRAC assay, was 
also calculated for this subset of samples (26 intestinal and 10 diffuse primary gastric 
tumors, 7 cell lines). The Kaplan Meier method and the log rank test were used to 
calculate the cumulative survival of patients showing ≥5-fold overexpression of a 
specific gene compared with patients showing <5-fold overexpression. A p-value 
<0.05 was considered statistically significant (SPSS 17.0). Survival information was 
available for 41 gastric cancer patients.  
 
7.3.3 Real-time qRT-PCR analysis (II, III) 
Real-time qRT-PCR was performed for six genes, including ALPK2, CXCL1, HHIPL2, 
SPARC, SPP1, and SULF1. ALPK2 and HHIPL2 were chosen based on their copy 
number-associated expression changes (Study II), and CXCL1, SPARC, SPP1, and 
SULF1 based on their overexpression in the Japanese and Finnish gastric cancer 
tissues compared with normal gastric tissues (Study III). The mRNA expression levels 
were  measured  in  82  gastric  tissues  (II,  III),  including  46  cancerous  and  36  
nonmalignant tissues, and in 7 gastric cancer cell lines (II). One microgram of total 
RNA was converted to cDNA, and the transcripts were quantitated using Assays-on-
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DemandTM gene expression products from Applied Biosystems (Foster City, CA, 
USA)  according  to  the  manufacturer’s  protocol.  All  primers  were  located  on  exon-
exon boundaries. Briefly, 2 µl of cDNA template was mixed with specific primers and 
probes labeled with FAM-reporter dye. Human 18S rRNA served as an endogenous 
control to normalize the expression levels in the subsequent quantitative analysis. 
The  18S  probe  was  labeled  with  VIC-reporter  dye  to  allow  multiplex  PCR  with  the  
target genes. Each sample was measured in triplicate, and the data were analyzed 
using the delta-delta method for comparing relative expression results (2–[Ct sample–Ct 
control]).  
 A nonparametric Mann-Whitney test was applied to measure the statistical 
significance of the differences in expression levels between nonmalignant and 
cancerous samples as well as between tumors of different histology and TNM stage 
(II, III). Nonmalignant (n=36) samples were compared with cancerous (n=46) 
samples, intestinal-type tumors (n=29) with diffuse-type tumors (n=16), T1-T2 
tumors (n=19) with T3-T4 tumors (n=24), N0 tumors (n=7) with N1-3 tumors (n=37), 
and metastasized tumors (n=7) with nonmetastasized tumors (n=37). In Study II, the 
expression levels of ALKP2 and HHIPL2 were also compared between cancer samples 
with copy number alterations (g1) and cancer samples with normal copy number (g0) 
to estimate the association between copy number and expression. Copy number 
data (obtained in Studies I and II) were available for 37 of the 46 cancer samples, (7 
cell lines, 23 intestinal and 7 diffuse primary gastric tumors). The Kaplan Meier 
method and the log rank test were used to calculate the cumulative survival of 
patients showing ≥5-fold overexpression of a specific gene compared with patients 
showing <5-fold overexpression. A p-value <0.05 was considered statistically 
significant (SPSS 17.0). Survival information was available for 34 gastric cancer 
patients.  
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8 RESULTS AND DISCUSSION 
8.1 Copy number alterations (I, II) 
Genome-wide gene copy number alterations in gastric cancer were measured both 
in Studies I and II. In Study I, the applied CGH array contained 12,000 cDNA probes 
(12K cDNA array), and both cancerous and normal gastric tissues were included in 
the analysis. The number of samples in different gastric cancer subgroups (intestinal 
vs. diffuse, antrum- vs. corpus-located cancers) was large enough for a subtype-
specific analysis to be performed. In Study II, the applied CGH array contained 
244,000 oligo probes (244K oligo array), thus improving the resolution of the analysis 
over 20-fold compared with Study I. This enabled a detailed measurement of the 
copy number aberration breakpoints and the size of the aberrations. In addition to 
the gastric cancer tissues, seven gastric cancer cell lines were included in the aCGH 
analysis in Study II.  
 
8.1.1 Copy number analysis with 12K cDNA CGH arrays (I) 
In  Study  I,  46  gastric  tissue  samples  (38  cancerous  and  8  nonmalignant)  were  
included in the copy number analysis performed with 12K cDNA arrays. The 
cancerous gastric tissues included 25 intestinal and 13 diffuse gastric tumors, and 19 
of these tumors were located in the antrum and 19 in corpus. Gene copy number 
aberrations were identified in all 38 gastric cancer samples. The most frequent gains 
were observed at 8q (16%), 17q12-q21 (13%), 20q (21%), and X (16%), and the most 
frequent losses at 4q (11%), as shown in Figure 6. The identified DNA copy number 
changes are in concordance with previous studies (Table 2).  
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Figure 6. DNA copy number change frequencies in 38 gastric adenocarcinomas using 12K 
cDNA CGH microarrays and CGH Explorer software. Frequency (%) of gains is shown in red 
and frequency (%) of losses in blue.  
 
8.1.1.1 Subtype-specific copy number alterations 
Gains at 17q12, 20q11.22-q13.33, and Xp were more common in the intestinal-type 
gastric cancer, whereas losses throughout the genome, and gains at 19q13.32 were 
more frequently observed in the diffuse-type cancer (Figure 7). The higher frequency 
of 17q12 and 20q gains in intestinal gastric cancer has also been reported in other 
studies (Kokkola et al., 1997; Maqani et al., 2006; Vauhkonen et al., 2006), whereas 
gains at Xp and 19q13.32 have not previously been linked to either histological 
subtype. In addition, copy number alterations of six individual genes, ERBB2 
(17q21.1), NAPA (19q13.32), GNAS (20q13.3), XK (Xp21.1), PTGIS (20q13.13), and 
one unknown gene (ENSG00000104866, 19q13.32), discriminated between intestinal 
and diffuse gastric cancers. With these genes, the proportion of correct histological 
classification  was  81.6%,  with  a  p-value  of  0.0002,  when  compared  with  randomly  
selected variables.  
To determine whether specific copy number alterations correlated with 
location of the tumor, we compared the frequencies of gains and losses in tumors 
located in different parts of the stomach. The frequency of gains at 17q21.2 was 
higher in the corpus, whereas gains at 8q24 and 20q13 were more frequent in the 
antrum. Interestingly, proximal gastrointestinal tumors, such as Barrett’s 
adenocarcinoma, are also known to contain amplifications in the 17q chromosomal 
region, whereas distal gastrointestinal tumors, such as colorectal cancer, have 
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frequent amplifications at 20q (Myllykangas et al., 2006). The location of these 
tumors in the gastrointestinal tract and perhaps a similar cell-of-origin might explain 
the similar molecular genetic alterations in these tumor types and in gastric cancers 
located in different regions of the stomach. In addition, copy number alterations of 
five individual genes, including SLC35C2 (20q13.12), BCAS1 (20q13.2), NEURL2 
(20q13.12), CYP24A1 (20q13), and one unknown gene (ENSG00000131747, 17q21.2), 
discriminated cancers located in the antrum from those located in the corpus. The 
corresponding proportion of correct location classification was 73.7% with a p-value 
of 0.0003. 
 
Figure 7. DNA copy number change frequencies in A) intestinal (n=25) and B) diffuse (n=13) 
gastric adenocarcinomas. Frequency (%) of gains is shown in red and frequency (%) of losses 
in blue. 
 
8.1.2 Copy number analysis with 244K oligo CGH arrays (II) 
In Study II, 13 gastric cancer tissue samples and 7 gastric cancer cell lines (AGS, 
KATOIII,  MKN-1,  MKN-7,  MKN-28,  MKN-45,  and  TMK-1)  were  included  in  the  copy  
number analysis performed with 244K oligo arrays. The cancerous gastric tissues 
included 9 intestinal and 4 diffuse gastric tumors, and 5 of these tumors were 
located in the antrum and 8 in the corpus. Copy number alterations were identified 
Results and Discussion 
 
 45
in 19 (95%) of the 20 samples including 12 of the 13 tissue samples (92.3%) and all 7 
cell lines. The recurrent (detected in ≥25% of samples) copy number alterations are 
shown in Table 4. The most frequent gains were observed at 8q (detected in 45% of 
the samples), 20q (40%), 7q (35%), and 19q (35%), and losses at 18q (40%) and 9p 
(35%). All of the recurrent copy number alterations were observed in both primary 
tissues  and  gastric  cancer  cell  lines,  except  for  the  gain  at  14q11.2,  which  was  
observed only in cell lines. The identified regions of DNA copy number changes are in 
concordance with previous studies (Table 2). However, we were able to map the 
breakpoints of the altered regions in greater detail than in the earlier studies, e.g. for 
the 8q and 18q regions, and some novel regions of copy number gains, such as 
14q11.2, were also identified.  
 
Table 4. Minimal common regions of copy number alterations, gain (+) and loss (-), observed 
≥25% of the gastric cancer samples. 
 
The copy number gains and losses identified with the 12K arrays were 
detectable also with the 244K arrays, thus showing a good concordance between 
these two array types. In general, however, the number of chromosomal regions 
Alteration Copy number 
aberration 
frequency (%) 
Size 
(Mb) 
Position (Mb) Possible target genes 
+1q41-q43.1 25 17.30 216.31−233.61 HHIPL2, ENAH, AGT, CAPN2, 
LEFTY2, LGALS8 
+5p13.3-q11.1 25 19.41 30.18−49.60 OSMR, RNASEN 
+7q21.3-q22.1 35 4.60 97.33−101.93 CYP3A4, AZGP1,VGF 
+8q24.13-q24.3 25 19.8 126.45-146.25 ASAP1, BAI1, KHDRBS3 
+8q24.3 45 2.23 143.59-145.82 GML, LYPD, AK3 
+14q11.2 25 1.05 22.89-23.94 LTB4R 
+17q12-q21.1 30 0.28 35.02−35.30 ERBB2, PPP1R1B, PERLD1, PNMT 
+17q22-q24.2 25 13.65 50.45-64.10 AXIN2, RNF43 
+19q12-qter 35 29.36 33.89−63.25 CEACAM5, APOC1, APOE, 
CEACAM7, FTL, FUT1, GPR4, HPN, 
KCNN4, KLK1, KLK12, LYPD3, 
NLRP7, CCNE1 
+20p13-qter 40 57.94 0.04−57.98 PTPRA, BLCAP, CD40, CHGB, CST3, 
EYA2, PI3, ID1, MMP9, BMP7 
-9p24.3-p21.1 35 27.81 1.05-28.86 MTAP, CD274, INSL4, JAK2, 
MLANA, SMARC2, TUSC1 
-18q12.3-q22.2 40 26.11 39.48−65.59 ALPK2, SMAD7, 
SERPINB2/B3/B4/B5 
-18q22.3-qter 35 3.69 70.95−74.65 TSHZ1 
-21q11.2-q21.1 30 4.07 14.37-19.44 HSPA13 
-Xq28 25 1.21 152.24-153.45 - 
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with  recurrent  copy  number  alterations  and  the  frequency  of  alterations  in  these  
regions was higher in Study II than in Study I, which is probably mainly due to the 
higher sensitivity of the 244K oligo arrays compared to the 12K cDNA arrays.  
  
8.2  Copy number-associated gene expression changes (I, II) 
The association of gene copy number and expression in gastric cancer was analyzed 
in  Studies  I  and  II.  Integration  of  gene  copy  number  and  expression  data  was  
performed to identify genes, whose transcriptional activation or repression is 
associated with a copy number change in a cancer cell. In Study I, the integration 
analysis  of  copy  number  and  expression  was  performed  on  a  genome-wide  scale,  
whereas in Study II, the focus was on recurrent (≥25%) copy number alterations, 
which occurred simultaneously with at least a 2-fold change (FC) in gene expression.  
 
8.2.1 Genome-wide association of copy number and expression (I) 
In Study I, the analysis of the association of copy number and gene expression 
alterations revealed 657 individual genes with a statistically significant association 
(α<0.05)  between  copy  number  gain  and  overexpression,  and  95  genes  with  a  
statistically  significant  association  (α<0.05)  between  copy  number  loss  and  
underexpression. Twenty-nine of these genes showed at least a 2-fold copy number-
associated change in their expression (Table 5).  
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Table 5. Potential gastric cancer target genes (n=29) showing a statistically significant 
association between copy number and expression, and at least a 2-fold copy number-
associated change in their expression in 38 primary gastric adenocarcinomas.  
Fold change = gene expression fold change between samples with copy number alterations (g1) and 
samples with normal copy number (g0). (-) copy number loss or underexpression, (+) copy number 
gain or overexpression. ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; UGC, upper 
gastrointestinal cancers (gastric and esophageal); TGCT, testicular germ cell tumor. 
 
Across the genome, 6.3% of deleted genes were underexpressed and 9.6% of 
amplified genes were overexpressed. This is in line with previous reports on the 
impact of copy number on gene expression in solid tumors (Hyman et al., 2002; Wolf 
et al., 2004; Järvinen et al., 2006; Yang et al., 2007; Järvinen et al., 2008; Tsukamoto 
et al., 2008). Two earlier studies have integrated genome-wide aCGH and gene 
expression microarray data in gastric cancer (Yang et al. 2007; Tsukamoto et al., 
2008). These studies reported a strong influence of both genomic amplification and 
Gene Copy number 
alteration 
Gene 
expression fold 
change g1 vs. g0 
Copy number 
aberration 
frequency (%) 
Examples of associated cancers 
MUC1 +1q22 +3.6 11 gastric, ovarian, breast, colorectal 
F5 +1q23 +4.5 13 - 
PHC3 +3q26.2 +3.6 13 osteosarcoma 
ECT2    +3q26.31 +2.2 13 esophageal 
CLDN1 +3q28 +2.6 11 colorectal 
MGST2 -4q28.3 -2.1 13 - 
VEGF  +6p21.1 +4.3 11 gastric, ovarian, breast, 
osteosarcoma 
HOXA9 +7p15.2 +3.1 13 ALL 
HOXA10 +7p15.2 +2.4 13 endometrial, breast 
SMURF1 +7q22.1 +2.1 13 pancreatic 
CYP3A4/5 +7q22.1 +2.0 13 prostate 
SQLE +8q24.1 +3.0 21 lung 
MYST4 +10q22.2 +2.2 11 AML 
TMEM16A  +11q13.3 +3.1 11 breast, pancreatic, gastric, 
parathyroid 
KCNJ8 -12p11.23 -3.3 11 - 
PPARBP  +17q12 +4.1 11 breast, gastric 
PPP1R1B +17q12 +8.3 18 gastric, UGC 
STARD3  +17q12 +3.9 18 breast, UGC  
PNMT     +17q12 +3.2 18 gastric, breast, adrenal 
PERLD1 +17q12 +7.9 18 gastric, breast 
ERBB2  +17q12 +3.7 21 gastric, breast, lung 
GRB7 +17q12 +2.4 18 gastric, pancreatic, TGCT 
TNS4 +17q21.2 +2.1 18 lung 
KRT23 +17q21.2 +3.1 13 pancreatic 
JUP  +17q21.2 +5.2 13 gastric, TGCT 
ZNF407 -18q23 -2.1 11 - 
PFDN4  +20q13.2 +2.4 21 breast  
GATA5 +20q13.33 +2.1 24 gastric, colorectal, ovarian, lung 
TKTL1  +Xq28 +2.2 11 colon, urethelial 
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deletion on gene expression. In gastric cancers, 25% of all genes showed copy 
number-associated gene expression changes, and 3.4% of these genes were located 
in the recurrent (>10%) regions of copy number alterations (Tsukamoto et al., 2008). 
Wolf  et  al.  (2004)  reported  that  across  the  genome,  copy  number  alterations  are  
significantly associated with gene expression alterations in prostate tumors, and that 
19.6% of the amplified genes showed overexpression. In addition, 12.1% of the 
genes with copy number losses were underexpressed. In head and neck cancers, 8% 
of genes with genomic losses were also downregulated (Järvinen et al., 2006). Thus, 
based on our results as well as on previous reports, the effect of copy number 
changes on gene expression in solid tumors is undisputable. However, the estimated 
extent of this interaction seems to be dependent on the tumor type as well as on the 
methods used in the integration analysis (e.g. the applied data analysis software and 
the threshold levels used to detect copy number alterations).   
 
8.2.2 Association of copy number and expression in recurrent regions of 
chromosomal alterations (II) 
In Study II, the integrated copy number and expression analysis focused on the 
chromosomal regions with recurrent (³25%) copy number alterations. Altogether 
256 individual genes (10% of all genes in regions with recurrent copy number 
alterations) showed at least a 2-fold change in gene expression that was associated 
with a gene copy number change; 226 of these genes were gained and 
overexpressed, and 30 genes contained losses and consequently were 
underexpressed. A literature search revealed that 50 of these genes (Table 6) have 
previously been described to have mutations, polymorphisms, copy number 
alterations, or gene expression changes in human tumors, and that fourteen of the 
identified genes (AGT, APOC1, APOE, AXIN2, CEACAM5, ERBB2, HSPA13, ID1, KLK12, 
MMP9, PPP1R1B, PTPRA, SERPINB5, and SMAD7) have been associated with gastric 
tumors.  
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Table 6. Potential gastric cancer target genes (n=50) identified by integrated microarray 
analysis of 13 primary gastric adenocarcinomas and 7 gastric cancer cell lines (II).  
Copy number 
alteration 
Gene Gene 
expression 
fold change 
Copy number 
aberration 
frequency (%) 
Examples of associated cancers 
+1q41-q42 CAPN2 +2.1 25 breast 
+1q42.1 LEFTY2 +2.1 25 colon, duodenum, ovarian 
+1q42.12 ENAH +4.2 25 breast, colorectal 
+1q42-q43 AGT +4.0 25 gastric 
+1q42-q43 LGALS8 +2.0 25 colon, lung 
+5p13.1 OSMR +2.1 25 ovarian 
+5p13.3 RNASEN +2.1 25 cervical, esophageal, ovarian 
+7q21.1 CYP3A4 +4.6 35 breast, lung, ovarian 
+7q22.1 AZGP1 +2.6 35 lung, prostate 
+8q24 BAI1 +4.3 45 glioblastoma 
+8q24.1-q24.2 ASAP1 +2.3 25 prostate 
-9p21 MTAP -2.2 35 breast, colon, pancreatic 
-9p21.2 TUSC1 -2.1 35 lung 
-9p22.3 SMARCA2 -2.9 35 lung, prostate 
-9p24 CD274 -4.4 35 esophageal, lung, ovarian 
-9p24 INSL4 -2.3 35 breast 
-9p24 JAK2 -2.6 35 breast 
-9p24.1 MLANA -2.7 35 melanoma 
+14q11.2-q12 LTB4R +2.1 25 ovarian, pancreatic 
+17q12 PPP1R1B +3.7 30 breast, gastric, UGC 
+17q21.1 ERBB2 +5.2 30 breast, gastric, lung, ovarian 
+17q22 RNF43 +2.5 25 colorectal 
+17q23-q24 AXIN2 +3.7 25 breast, colorectal, gastric 
-18q21.1 SMAD7 -2.1 40 colorectal, gastric, prostate 
-18q21.3 SERPINB2 -2.2 40 endometrial 
-18q21.3 SERPINB3 -4.3 40 esophageal 
-18q21.3 SERPINB4 -4.0 40 cervical, hepatocellular, skin 
-18q21.3 SERPINB5 -2.7 40 breast, gastric, lung 
+19q11-q13.2 HPN +4.5 35 prostate 
+19q12 CCNE1 +3.0 35 breast, glioma, pancreatic 
+19q13.1-q13.2 CEACAM5 +2.2 35 colorectal, gastric, lung 
+19q13.2 APOC1 +3.2 35 gastric, ovarian, pancreatic 
+19q13.2 APOE +4.7 35 breast, gastric, lung, ovarian 
+19q13.2 CEACAM7 +11.3 35 colorectal 
+19q13.2 KCNN4 +2.7 35 endometrial 
+19q13.3 FTL +3.8 35 osteosarcoma 
+19q13.31 LYPD3 +3.6 35 esophageal, lung 
+19q13.3-q13.4 KLK12 +8.5 35 breast, gastric, prostate 
+19q13.42 NLRP7 +4.7 35 endometrial, testicular 
+20p11.21 CST3 +2.8 40 breast, prostate 
+20p13 PTPRA +2.1 40 gastric 
+20pter-p12 CHGB +2.1 40 breast 
+20q11 ID1 +2.2 40 colorectal, gastric, prostate 
+20q11.2-q12 BLCAP +2.2 40 cervical 
+20q11.2-q13.1 MMP9 +7.3 40 breast, colorectal, gastric 
+20q12-q13 PI3 +3.6 40 glioblastoma 
+20q12-q13.2 CD40 +2.9 40 colon, lung, ovarian 
+20q13 BMP7 +2.5 40 breast, colorectal, prostate 
+20q13.1 EYA2 +3.2 40 ovarian 
-21q11 HSPA13 -2.3 30 gastric 
(-) copy number loss or underexpression, (+) copy number gain or overexpression.  
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The highest copy number gain-associated upregulation was detected for 
HHIPL2 (HHIP-like 2) (FC 26.9) in the 1q41-q43.1 region. Generally, the highest gene 
expression fold changes between samples with and without copy number alterations 
were observed at the 19q region since 19 of the 40 genes (47.5%)  showing at least a 
5-fold copy number related change in their expression were located in the 19q 
region. Other chromosomal regions in which several genes showed ≥5-fold copy 
number-associated gene expression changes were 20p13-qter with 6 upregulated 
genes, 5p13.3-q11.1 with 4 genes, and 1q41-q43.1 and 18q12.3-q22.2, both with 3 
genes. The highest copy number loss-related downregulation (FC -34.6) was 
detected for the ALPK2 (alpha-kinase 2) gene of the 18q12.3-q22.2 region.  
Two previous gastric cancer studies have systematically integrated genome-
wide aCGH and gene expression microarray data to identify genes whose expression 
had changed due to copy number alteration (Yang et al., 2007a; Tsukamoto et al., 
2008). Comparison of the overlapping genes between these studies and Studies I and 
II revealed 30 genes, including ANP32E, APH1A, MRPS21, MCL1 (1q21.2), TOMM20 
(1q42), GGPS1 (1q43), LMBRD2 (5p13.2), CCND3 (6p21), MTMR9 (8p22-p23.1), MTAP 
(9q21.3), MAZ (16p11.2), CASC3, GRB7, ERBB2, FBXL20, GSDML, ORMDL3, PERLD1, 
PPARBP, PSMD3, RAPGEFL1, RARA, SMARCE1, THRA, STARD3, CDC6 (17q12-q21), 
ACTR5 (20q11.23), DDX27 (20q13.13), PARD6B (20q13.13), and ADNP (20q13.3), 
either gained and overexpressed or deleted and underexpressed in Studies I or II and 
in at  least  one of  the previous studies (Yang et  al.,  2007a;  Tsukamoto et  al.,  2008).   
Former published data together with the current results provide strong evidence of 
the biological role of these genes in gastric cancer. 
 
8.3 Genome-wide gene expression changes (III) 
Specific gastric cancer-related gene expression profiles have previously been 
correlated with histology (Hippo et al., 2002; Boussioutas et al., 2003; Chen et al., 
2003; Kim et al., 2003; Jinawath et al., 2004), invasiveness (Hasegawa et al., 2002; 
Hippo  et  al.,  2002),  and  survival  (Chen  et  al.,  2003;  Tay  et  al.,  2003;  Vecchi  et  al.,  
2007),  and  a  large  number  of  genes  with  a  potential  role  in  gastric  carcinogenesis  
have been reported. However, the number of common genes reported in these 
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studies is rather low, which is most likely due to the variation in patient populations, 
processing of the samples, used microarray platforms, and analysis principles. Genes 
identified as differentially expressed irrespective of the used microarray platform, 
and in different patient populations, could prove to be the most robust and the most 
promising clinical biomarker candidates for gastric cancer. 
Thus, in Study III, we performed a genome-wide gene expression analysis of 
Finnish and Japanese primary gastric tumors to identify genes associated with gastric 
cancer in both Finnish and Japanese gastric cancer material. The Finnish samples 
were analyzed on Agilent 2-color gene expression arrays and Japanese samples on 1-
color Affymetrix expression arrays. Genome-wide expression changes were 
measured to determine gastric cancer-related up- or downregulation of potential 
target genes. Furthermore, we obtained a third unrelated gastric cancer data set 
(Agilent 1-color array, Tsukamoto et al. 2008), re-analyzed it, and compared the 
results with our own two datasets, to find common gene expression alterations and 
thus promising novel target genes for gastric cancer.  
 
8.3.1 Common alterations in Finnish and Japanese gastric cancers (III) 
Comparative analysis of the Finnish and Japanese gastric tissue samples revealed 58 
genes that were differentially expressed in cancerous vs. nonmalignant gastric 
tissues in our two data sets (Table 7). Of these genes, 26 were overexpressed and 32 
underexpressed in cancer. The differentially expressed genes identified in our study 
showed a good correlation with another gene expression microarray data set 
(Tsukamoto et al., 2008) since the majority (64%, n=37) of the genes identified in our 
study were also differentially expressed in this unrelated data set (Table 7). These 37 
commonly up- and downregulated genes included 17 genes (CAPN9, COL1A1, 
COL1A2, COL3A1, CTSK, IFITM1, IGFBP7, MAL, MUC5AC, PDGFRB, RAB31, SLC7A8, 
SPARC, SPP1, SST, SULF1, and THBS2) previously reported as differentially expressed 
in gastric cancer compared with normal gastric tissues (Boussioutas et al., 2003; Kim 
et al., 2003; Tay et al., 2003, Jinawath et al., 2004; Krueger et al., 2005; Yang et al., 
2005; Higashiyama et al., 2007; Yang et al., 2007a;  Yang  et  al., 2007c; Chen et al., 
2009)  as  well  as  20  novel  gastric  cancer-related  genes  (ABCC5, ATP4A, CAPN13, 
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CMTM4, COL5A2, CXCL1, DHCR24, DPCR1, EPN3, KIAA1949, LOC400451, MYOC, 
NEDD4L, PDIA2, PKIB, SLC44A2, TMEM171, VSIG1, VSIG2, and XK).  The  six  most  
highly expressed (median FC>3.0) genes in these three data sets (Finnish (n=46), 
Japanese (n=20) and Tsukamoto et al. (2008) (n=29)) were CXCL1 (FC 9.4), COL1A2 
(FC 5.6), SULF1 (FC 5.5), COL1A1 (FC 4.8), SPP1 (FC 4.3), COL3A1 (FC 4.0), SPARC (FC 
3.6), and THBS2 (FC 3.3).  
 
8.3.2 Gene ontology analysis (III) 
Gene ontology analysis showed that the differentially expressed genes in our two 
data sets represent many biological processes (BP) and molecular functions (MF) 
relevant to carcinogenesis such as cell adhesion, cell proliferation, extracellular 
matrix organization, and growth factor binding (Table 8). These GO terms were 
enriched (p<0.05) among the differentially expressed genes in the Finnish and 
Japanese gastric tumors.  
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Table 7. Fifty-eight common differentially expressed genes in Finnish and Japanese primary 
gastric cancers. The 37 genes differentially expressed in all three microarray data sets 
(Finnish, Japanese, and Tsukamoto et al., 2008) are underlined.  
Symbol Location 
Fold change in 
Japanese 
cases 
Fold change in 
Finnish cases 
p-value in 
Japanese 
cases 
p-value in 
Finnish 
cases 
ABCA1 9q31.1 +3.1 +2.2 0.0463 0.0023 
ABCC5 3q27 -3.1 -3.1 0.0484 0 
AGPAT9 4q21.23 -3.2 -1.6 0.0484 0.008 
ATP4A 19q13.1 -33.7 -184.9 0.0425 0 
CAPN13 2p22-p21 -4.1 -1.7 0.0229 0.0007 
CAPN9 1q42.11-q42.3 -11.1 -1.6 0.0299 0.0053 
CDH11 16q22.1 +5.8 +2.3 0.0164 0.0102 
CMTM4 16q22.1 -2.3 -2.0 0.0484 0 
COL1A1 17q21.33 +4.8 +4.9 0.0199 0 
COL1A2 7q22.1 +6.4 +5.6 0.0091 0 
COL3A1 2q31 +4.6 +4.0 0.0164 0.0004 
COL4A2 13q34 +3.6 +2.4 0.0252 0.0001 
COL5A1 9q34.2-q34.3 +4.3 +1.4 0.0217 0.0131 
COL5A2 2q14-q32 +4.5 +2.3 0.0282 0.0012 
CTSK 1q21 +5.3 +1.7 0.0255 0.0233 
CXCL1 4q21 +9.4 +3.2 0.0199 0.0023 
CYP2C18 10q24 -10.5 -1.7 0.0199 0.0003 
DHCR24 1p33-p31.1 -3.8 -2.0 0.0429 0.0007 
DPCR1 6p21.33 -15.3 -3.7 0.0255 0.0032 
ELOVL6 4q25 -4.2 -1.8 0.0231 0.0003 
EPN3 17q21.33 -3.3 -2.4 0.0229 0 
FA2H 16q23 -2.0 -2.0 0.0484 0.0328 
FMO5 1q21.1 -3.3 -1.6 0.0425 0.0004 
GEM 8q13-q21 +7.0 +1.8 0.0164 0.005 
IFITM1 11p15.5 +2.6 +2.7 0.0282 0.001 
IGFBP7 4q12 +3.8 +2.4 0.0173 0.0204 
IL1R2 2q12-q22 -6.1 -1.5 0.0425 0.0366 
KIAA1949 15q24 +4.3 +1.8 0.046 0.0101 
LOC400451 15q26.1 -2.3 -1.9 0.0425 0.0002 
MAL 2cen-q13 -7.4 -3.8 0.046 0 
MUC5AC 11p15.5 -11.2 -3.4 0.0255 0.0045 
MXRA5 Xp22.33 +2.7 +2.0 0.0249 0.01 
MYOC 1q23-q24 -2.6 -1.8 0.0463 0.0071 
NEDD4L 18q21 -2.7 -2.3 0.0396 0 
OLFML2B 1q23.3 +4.9 +1.6 0.0376 0.0003 
PDGFRB 5q31-q32 +2.8 +2.9 0.0232 0.0001 
PDIA2 16p13.3 -7.4 -2.1 0.0252 0 
PKIB 6q22.31 -2.8 -1.9 0.0461 0.0004 
PLXDC1 Xp22.33 +2.6 +2.0 0.0282 0.0114 
PMEPA1 20q13.31-q13.33 +3.1 +2.3 0.0385 0.016 
RAB31 18p11.3 +3.0 +2.2 0.0484 0.001 
RASEF 9q21.32 -5.2 -3.7 0.0425 0 
RASSF6 4q13.3 -5.1 -1.4 0.0199 0.0141 
SERINC2 1p35.1 -2.5 -1.4 0.0484 0.0192 
SFRP4 7p14.1 +5.9 +4.0 0.0444 0.0032 
SLC44A2 19p13.1 -2.4 -1.4 0.0219 0.0362 
SLC7A8 14q11.2 -2.6 -2.5 0.0219 0 
SPARC 5q31.3-q32 +4.1 +3.6 0.0196 0.0002 
SPP1 4q21-q25 +14.2 +2.5 0.0232 0.0243 
SST 3q28 -15.6 -1.9 0.0458 0.0115 
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SULF1 8q13.2-q13.3 +9.6 +3.9 0.0229 0.0001 
SYTL2 11q14 -2.7 -1.9 0.0484 0.0221 
THBS2 6q27 +19.1 +1.8 0.0091 0.0276 
THY1 11q22.3-q23 +5.9 +2.0 0.0226 0.0003 
TMEM171 5q13.2 -3.3 -1.7 0.0476 0.0001 
VSIG1 Xq22.3 -9.9 -2.9 0.0229 0 
VSIG2 11q24 -12.3 -2.8 0.0173 0 
XK Xp21.1 -5.3 -1.6 0.0252 0.0268 
Fold change = gene expression fold change between cancerous and nonmalignant samples. (+) 
overexpression, (-) underexpression. 
 
Table 8. Enriched biological process (BP) and molecular function (MF) gene ontology terms 
in Finnish and Japanese gastric cancers. The number of differentially expressed genes 
belonging to each enriched (p<0.05) GO-category is shown. 
GO, gene ontology 
 
GO term GO Description 
p-value 
in 
Japanese 
cases 
p-value 
in 
Finnish 
cases 
No. of 
genes in 
Japanese 
cases 
No. of 
genes in 
Finnish 
cases 
GO:0008154 (BP) Actin polymerization and/or 
depolymerization 
0.012 0.017 3 15 
GO:0022610 (BP) Biological adhesion 0.000 0.009 19 129 
GO:0007155 (BP) Cell adhesion 0.000 0.009 11 124 
GO:0008283 (BP) Cell proliferation 0.037 0.027 3 28 
GO:0007586 (BP) Digestion 0.040 0.000 3 28 
GO:0030198 (BP) Extracellular matrix 
organization and biogenesis 
0.007 0.047 3 12 
GO:0002376 (BP) Immune system process 0.031 0.000 12 172 
GO:0006817 (BP) Phosphate transport 0.000 0.029 11 21 
GO:0051338 (BP) Regulation of transferase 
activity 
0.035 0.018 5 44 
GO:0003823 (MF) Antigen binding 0.005 0.031 3 11 
GO:0004197 (MF) Cysteine-type 
endopeptidase activity 
0.003 0.004 4 20 
GO:0008234 (MF) Cysteine-type peptidase 
activity 
0.027 0.034 4 30 
GO:0004175 (MF) Endopeptidase activity 0.036 0.000 7 95 
GO:0005201 (MF) Extracellular matrix 
structural constituent 
0.000 0.000 10 30 
GO:0005539 (MF) Glycosaminoglycan binding 0.000 0.016 7 24 
GO:0019838 (MF) Growth factor binding 0.000 0.036 5 17 
GO:0008201 (MF) Heparin binding 0.000 0.002 7 22 
GO:0005506 (MF) Iron ion binding 0.022 0.031 6 51 
GO:0016491 (MF) Oxidoreductase activity 0.032 0.001 11 135 
GO:0001871 (MF) Pattern binding 0.000 0.028 3 24 
GO:0030247 (MF) Polysaccharide binding 0.000 0.013 7 25 
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8.4 Potential gastric cancer target genes (I-III) 
8.4.1 Validation of gastric cancer-related proteins (I) 
In  Study  I,  the  expression  levels  of  two  target  genes,  ERBB2 and MUC1, were 
measured using a tissue microarray and immunohistochemistry to identify 
differences in their protein expression between different histological subtypes and 
tumor locations. These two genes were chosen for validation because they showed 
statistically significant associations between copy number and expression changes in 
the integrated microarray analysis (I). The TMA analysis was successful for 64 and 68 
samples  stained  with  MUC1-  and  ERBB2-specific  antibodies,  respectively.  MUC1  
showed  positive  immunostaining  in  70%  and  ERBB2  in  31%  of  gastric  tumors,  
respectively. Both MUC1 and ERBB2 showed positive staining more frequently in 
intestinal-  than  in  the  diffuse-type  gastric  cancer  (70%  vs.  41%  for  MUC1,  31%  vs.  
14% for ERBB2). Neither ERBB2 nor MUC1 was differentially expressed in tumors 
located in the proximal (corpus and cardia) versus the distal (antrum) parts of the 
stomach. Overall, the results from immunohistochemical analysis of MUC1 and 
ERBB2 were in concordance with the results of the integrated copy number and gene 
expression analysis (I) and illustrated that copy number amplification also leads to 
higher protein expression of these genes in gastric cancer.  
ERBB2  phosphorylates  MUC1  (Li  et  al., 2001; Schroeder et al., 2001) and 
thereby regulates the interaction between MUC1 and β-catenin (Yamamoto et al., 
1997). In addition, H. pylori has been shown to bind MUC1 and activate β-catenin in 
gastric  epithelial  cells.  Therefore,  after  being  activated  by  a  copy  number  gain,  
ERBB2, or H. pylori infection, MUC1 might promote proliferation and invasion 
through an interaction with β-catenin in gastric carcinogenesis. ERRB2 (also known 
as HER2) is a receptor tyrosine kinase that is amplified and overexpressed in a 
number of solid tumors, including gastric tumors (Menard et al., 2001; Takehana et 
al., 2002; Varis et al., 2004; Park et al., 2006). ERBB2 is known to activate a number 
of signaling pathways involved in cellular growth, proliferation, and differentiation 
such as Ras/Raf/Erk and PI3K/Akt (Prigent et al., 1994; Ricci et al., 1995; Bentires-Alj 
et  al.,  2006).  In  breast  cancers,  ERBB2 amplification predicts poor prognosis 
(Paterson et al., 1991). An Anti-HER2 monoclonal antibody, Trastuzumab, has been 
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reported to reduce tumor volume in breast cancer (Slamon et al., 2001; Vogel et al., 
2002), and to inhibit tumor growth in gastric cancer cell lines and in one patient with 
ERBB2 amplification and overexpression (Kong et al., 2004; Rebischung et al., 2005). 
Gastric cancer patients with ERBB2 amplification and overexpression may therefore 
prove to be potential candidates for anti-HER2 monoclonal antibody therapy in the 
future.  
 
8.4.2 Validation of gastric cancer-related mRNAs (II, III) 
In Study II, the integration of high resolution copy number and gene expression 
microarray analysis revealed 256 genes that showed copy number-associated gene 
expression changes. Based on this data, 13 genes were chosen for further validation. 
The two genes showing the highest copy number-associated gene expression 
changes, ALPK2 and HHIPL2, were validated with real-time qRT-PCR. The other 
eleven genes, including ASAP1, CEACAM5, CYP3A4, ENAH, ERBB2, LTB4R, MMP9, 
OSMR, PERLD1, PNMT and PTPRA,  were  validated  using  the  TRAC  assay.  With  the  
TRAC assay, the expression levels of multiple genes can be measured simultaneously 
from a single sample, thus lowering the amount of sample RNA required for the 
analysis.  This  is  especially  important  for  the  analysis  of  often  scarce  clinical  tissue  
samples.  TRAC  assay  has  previously  been  shown  to  correlate  well  with  the  
conventional qRT-PCR and Northern blot analyses (Kataja et al., 2006; Rautio et al., 
2006).  
In Study III, 37 genes showed gastric cancer-related gene expression changes 
in all three data sets (Finnish, Japanese and Tsukamoto et al., 2008). The most highly 
overexpressed (median FC>3.0) genes included CXCL1, SULF1, SPP1, and SPARC. The 
expression of these four genes was further validated with the real-time qRT-PCR 
analysis.  
The 17 genes analyzed with TRAC assay or real-time qRT-PCR in Studies II and 
III, and their biological functions are summarized in Table 9. All of these genes 
showed statistically significant differences in their mRNA expression in nonmalignant 
versus  cancerous  gastric  tissue  samples  according  to  the  TRAC  assay  or  real-time  
qRT-PCR  analysis  (Table  10).  The  overexpression  in  cancer  samples  compared  with  
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nonmalignant  samples  ranged  from  1.9-  to  45.4-fold  (Table  10).  The  highest  
overexpression was detected for SPP1. In addition, SPP1 was overexpressed in 
metastasized tumors (FC 1.4). This is in line with the previous reports of SPP1’s role 
as a promoter of angiogenesis and metastasis in gastric cancer (Higashiyama et al., 
2007; Tang et al., 2007; Tang et al., 2008). Neither invasiveness (T) nor lymph node 
metastasis (N) had a significant effect on gene expression of these 17 genes, nor did 
histology of the tumor tissue (intestinal vs. diffuse) (Table 10).  
 
Table 9. The 17 genes analyzed with TRAC assay or real-time qRT-PCR analysis in Studies II 
and III. 
Gene 
symbol 
Gene name Chromosome 
location 
Biological role 
ALPK2 Alpha-kinase 2 18q21.31-q21.32 Unknown 
ASAP1 ADP-ribosylation factor GTPase 
activating protein 
8q24.1-q24.2 Cell motility and invasion 
CEACAM5 Carcinoembryonic antigen-related cell 
adhesion molecule 5 
19q13.1-q13.2 Cell adhesion 
CYP3A4 Cytochrome P450, family 3, subfamily 
A, polypeptide 4 
7q21.1 Metabolism of drugs and 
carcinogens 
CXCL1 Chemokine (C-X-C motif) ligand 1 
(melanoma growth stimulating 
activity, alpha) 
4q21 Regulation of the 
immune system and 
angiogenesis 
ENAH Enabled homolog (Drosophila) 1q42.12 Cell motility and invasion 
ERBB2 v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 2 
17q21.1 Receptor tyrosine kinase 
HHIPL2 HHIP-like 2 1q41 Unknown 
LTB4R Leukotriene B4 receptor 14q11.2-q12 Inflammation 
MMP9 Matrix metallopeptidase 9 20q11.2-q13.1 Tissue remodeling, cell 
invasion 
OSMR Oncostatin M receptor 5p13.1 Inflammation, cell 
proliferation  
PERLD1 per1-like domain containing 1 17q12 Unknown 
PNMT Phenylethanolamine N-
methyltransferase 
17q21-q22 Regulation of 
epinephrine production 
PTPRA Protein tyrosine phosphatase, 
receptor type, A 
20p13 Regulation of integrin 
signaling, cell adhesion 
and proliferation 
SPARC Secreted protein, acidic, cysteine-rich 
(osteonectin) 
5q31.3-q32 Tissue renewal and 
tissue remodeling 
SPP1 Secreted phosphoprotein 1 
(osteopontin) 
4q21-q25 Tissue renewal and 
tissue remodeling 
SULF1 Sulfatase 1 8q13.2-q13.3 Cell proliferation, cell 
signaling  
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Table 10. Results of the nonparametric Mann-Whitney test for the 17 genes analyzed with 
TRAC assay or real-time qRT-PCR. Cancer vs. nonmalignant, intestinal vs. diffuse, g1 vs. g0, 
M1 vs. M0, T1-2 vs. T3-4, and N0 vs. N1-3 comparisons are shown.  
Gene Cancer vs. 
nonmalignant 
Intestinal 
vs. diffuse 
g1 vs. g0 M1 vs. 
M0 
T1-2 vs. 
T3-4 
N0 vs. N1-3 
IIALKP2 p<0.05 (FC 1.9) p=0.104 p<0.05 p=0.451 p=0.072 p=0.378 
IIASAP1 p<0.001 (FC 6.6) p=0.319 p=0.396 p=0.208 p=0.232 p=0.289 
IICEACAM5 p<0.001 (FC 9.6) p=0.061 p=0.254 p=0.543 p=0.197 p=0.253 
IICYP3A4 p<0.001 (FC 8.9) p=0.061 p<0.05 p=0.355 p=0.228 p=0.422 
IIICXCL1 p<0.001 (FC 12.3) p=0.500 n/a p=0.153 p=0.340 p=0.229 
IIENAH p<0.001 (FC 8.4) p=0.290 p<0.05 p=0.149 p=0.949 p=0.342 
IIERBB2 p<0.001 (FC 3.5) p=0.168 p<0.05 p=0.490 p=0.350 p=0.314 
IIHHIPL2 p<0.05 (FC 7.4) p=0.248 p<0.05 p=0.847 p=0.129 p=0.736 
IILTB4R p<0.001 (FC 3.5) p=0.427 p=0.422 p=0.468 p=0.452 p=0.604 
IIMMP9 p<0.001 (FC 4.8) p=0.495 p<0.05 p=0.089 p=0.496 p=0.238 
IIOSMR p<0.001 (FC 3.4) p=0.548 p<0.05 p=0.182 p=1.000 p=0.184 
IIPERLD1 p<0.001 (FC 3.4) p=0.316 p<0.05 p=0.437 p=0.208 p=0.161 
IIPNMT p<0.001 (FC 2.4) p=0.649 p=0.346 p=0.133 p=0.824 p=0.136 
IIPTPRA p<0.001 (FC 4.1) p=0.304 p<0.05 p=0.112 p=0.953 p=0.596 
IIISPARC p<0.001 (FC 8.6) p=0.258 n/a p=0.835 p=0.261 p=0.553 
IIISPP1 p<0.001 (FC 45.4) p=0.485 n/a p<0.05 p=0.156 p=0.327 
IIISULF1 p<0.001 (FC 11.6) p=0.336 n/a p=0.282 p=0.751 p=0.344 
g1, samples with copy number gain/loss; g0, samples with normal copy number; FC, gene expression 
fold change between cancerous and nonmalignant gastric samples; II = Study II; III = Study III. 
 
 
SPP1 (osteopontin) and SPARC (osteonectin) both belong to the group of bone 
matrix-associated factors (Denhardt et al., 1993; Lane et al., 1994). They are 
expressed primarily during tissue renewal and tissue remodeling (Bornstein, 1995), 
and  are  able  to  bind  type  I  collagens  such  as  COL1A1  and  COL1A2  (Termine  et  al., 
1981;  Chen  et  al., 1992). COL1A1 and COL1A2 were among the most highly 
overexpressed genes identified in Study III (Table 7), and thus, the interactions 
between these four genes might be important for communication between tumor 
cells and the surrounding tissue matrix.  SPARC overexpression in gastric cancers has 
also been reported by Wang et al. (2004), who detected a 4.27-fold overexpression 
of this gene in tumor tissue compared with nonmalignant tissue.  
 Overexpression of ALPK2, CYP3A4, CXCL1, ENAH, HHIPL2, LTB4R, OSMR, and 
SULF1 in gastric cancer compared with nonmalignant tissue has not been previously 
reported. The highest overexpression of these genes was detected for CXCL1 (FC 
12.3) and SULF1 (FC  11.6).  Eck  et  al. (2003) noted that protein-level expression of 
CXCL1 was significantly higher in the diffuse subtype than in the intestinal subtype of 
gastric cancer, but no normal samples were included in their study. Surprisingly, 
even though gastric cancers in general showed overexpression of this gene 
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compared with normal tissues in our data, among gastric cancer patients better 
survival seemed to be associated with patients showing higher (≥5-fold) 
overexpression of this gene (Figure 8). Acosta et al. (2008) reported that signaling by 
CXCL1 (also known as GROα) reinforces senescence early in tumorigenesis and might 
thereby inhibit tumor growth. This could explain the dual role of CXCL1 in 
carcinogenesis.  It  may  also  be  suggested,  that  CXCL1 overexpression  plays  a  
protective role in normal cells against gastric tumorigenesis since gastric cancers 
with the highest overexpression (≥5-fold) of CXCL1 clearly show a better survival. 
This is extremely interesting since there are no previous reports than link CXCL1 to 
the cancer survival. This association of CXCL1 expression and cumulative survival 
might therefore prove to be clinically relevant. No association between the 
overexpression (≥5-fold vs. <5-fold) of the other 16 genes (analyzed with TRAC assay 
or qRT-PCR) and cumulative survival was found (data not shown). 
 
Figure 8. Cumulative 5-year survival of gastric cancer patients according to the CXCL1 gene 
expression. 
 
SULF1 modifies heparan sulphate proteoglycans (HSPGs), and this leads to 
changes in HSPG-related signal transductions. Therefore, deregulation of SULF1 may 
have a significant impact on cell growth and carcinogenesis (Dai et al., 2005; Chen et 
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al., 2009). Hypermethylation and consequential downregulation of SULF1 in gastric 
and breast cancers have been reported (Narita et al., 2007; Chen et al., 2009). 
However, in Study III, SULF1 expression was 11.6-fold higher in gastric cancer tissues 
than in nonmalignant gastric tissues (Table 10). This is the first study to report gastric 
cancer-associated overexpression of this gene. However, in hepatocellular cancers, 
upregulated SULF1 expression has been suggested to be related to MYC oncogene 
amplification (Lai et al., 2004). These two genes are located close to each other on 
the 8q chromosome arm, which is frequently amplified in gastric cancers (Weiss et 
al., 2004; Tsukamoto et al., 2008). MYC has been reported to be amplified in 26-30% 
of gastric tumors (Koo et al., 2000; Kozma et al., 2001), and coamplification of MYC 
and SULF1 might therefore explain the overexpression of SULF1 also in gastric 
cancers. 
In Study II, using TRAC assay and qRT-PCR analysis, the association of copy 
number and gene expression could be validated for nine of the thirteen tested genes 
(69.2%), including ALKP2, CYP3A4, ENAH, ERBB2, HHIPL2, MMP9, PERLD1, PTPRA, 
and OSMR (p<0.05) (Table 10). The overexpression in cancer samples with copy 
number gains compared with cancer samples with normal copy number ranged from 
1.7- to 17.4-fold, and the underexpression of ALPK2 in cancer samples with copy 
number loss was 2.9-fold (Table 11).  
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Table 11. Genes with copy number-associated expression changes (p<0.05) in gastric cancer 
according to the TRAC assay or real-time qRT-PCR analysis (II).  
Gene Fold change 
(cancer vs. 
normal) 
Fold change  
(g1 vs. g0) 
Previous reports in gastric 
cancer 
PubMed IDs 
ALPK2 +1.9 -2.9 - - 
CYP3A4 +8.9 +2.4 polymorphisms 17605821 
ENAH +8.4 +3.8 - - 
ERBB2 +3.5 +1.8 amplification, 
overexpression 
14991576, 19156142, 
17555797 
HHIPL2 +7.4 +17.4 - - 
MMP9 +4.8 +1.7 overexpression, 
polymorphisms 
18437914, 18451255, 
16237750 
OSMR +3.4 +2.4 - - 
PERLD1 +3.4 +3.0 amplification, 
overexpression 
16849520 
PTPRA +4.1 +1.3 overexpression 16338072 
Fold change = gene expression fold change between the two compared groups (cancer vs. 
nonmalignant, g1 vs. g0) according to the TRAC assay or qRT-PCR analysis; g1, samples with copy 
number gain/loss; g0, samples with normal copy number; (+) overexpression, (-) underexpression.  
 
 
ERBB2,  which  was  also  identified  as  one  of  the  most  potential  gastric  cancer-
associated genes is Study I, showed a 3.5-fold overexpression in gastric cancers 
compared with nonmalignant gastric tissues (p<0.001) according  to the TRAC assay 
in Study II (Table 10). The frequency of copy number gain of EBBB2 was  30%  (II)  
(Table 4), and the expression of ERBB2 was a 1.8-fold higher in gastric cancers with 
copy number gain of ERBB2 compared with cancers with normal copy number ERBB2 
(Table 11). However, unlike in Study I, an association between the expression levels 
of ERBB2 and histological subtype was not detected (Table 10). This might be due to 
smaller amount of samples included in Study II (40 intestinal and 13 diffuse gastric 
tumors) compared with study I (49 intestinal and 29 diffuse gastric tumors). There 
was also no association between ERBB2 expression and tumor stage.  
Copy number-related gene expression changes have not been previously 
reported for 7 out of the 9 genes identified in Study II (Table 11), including ALKP2, 
CYP3A4, ENAH, HHIPL2, MMP9, PTPRA and OSMR. Of these, ALPK2, HHIPL2, OSMR 
and ENAH are especially interesting since there are no previous publications that link 
these genes to gastric carcinogenesis. The frequency of copy number loss of ALPK2 in 
our  data  was  40%  (II)  (Table  4).  ALPK2 is located in the 18q12.3-q22.2 region, a 
region of recurrent genomic loss in gastric cancers (Table 2). No publications 
regarding the possible cancer association of ALPK2 or its function in normal tissues 
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exist.  The  18q  region  is  also  known  to  harbor  two  well-known  gastric  cancer-
associated tumor suppressor genes DCC (18q21.3) and SMAD4 (18q21.1) (Hidaka et 
al., 2003; Kimura et al., 2004; Yang et al., 2007a). However, these genes did not show 
copy number loss-associated underexpression in our data. 
HHIPL2 is a transmembrane protein containing a short N-terminal cytoplasmic 
region. It belongs to the HHIP gene family and is expressed in testis, thyroid gland, 
osteoarthritic cartilage as well as in pancreatic and lung cancers (Katoh and Katoh, 
2006). The frequency of copy number gain of HHIPL2 in our data was 25% (II) (Table 
4). Overexpression of HHIPL2 has not been previously associated with any cancers 
and its biological function is not known. However, another member of the HHIP 
family, HHIP1, is known to interact with proteins of the Hedgehog signaling pathway 
(Katoh  and  Katoh,  2006).  This  association  could  offer  an  explanation  also  for  
HHIPL2’s role in gastric cancer.  
Oncostatin M (OSM) is a member of the interleukin-6 cytokine family that binds 
to its receptor, OSMR, to induce signals important to hematopoiesis, inflammation, 
bone remodeling, heart development, and neurogenesis (Morikawa et al., 2004), 
whereas ENAH is an actin binding protein involved in the regulation of cell motility 
(Urbanelli et al., 2006). Both OSMR and ENAH were amplified in 25% of our primary 
gastric tumors and gastric cancer cell lines (II) (Table 4). OSMR and ENAH showed a 
statistically significant overexpression in gastric cancer samples with copy number 
gains compared with cancer samples with a normal copy number (FC 2.4 for OSMR 
and 3.8 for ENAH)  as  well  as  in  gastric  cancers  in  general  compared  with  normal  
gastric  tissues  (FC  3.4  for  OSMR and 8.4 for ENAH)  (Tables  10  and  11).  OSMR  has  
earlier been reported to be amplified and overexpressed only in cervical squamous 
cell  carcinomas,  where overexpression was associated with poor survival  (Ng et  al., 
2007b). Overexpression of ENAH has  previously  been  described  only  in  breast  
cancers (Di Modugno et al., 2006). These two genes could therefore represent 
completely novel target genes for gastric cancer.  
Summary and Conclusions 
 
 63
9 SUMMARY AND CONCLUSIONS 
To conclude, multiple chromosomal regions with frequent copy number alterations 
were detected in Studies I and II. Using high-resolution genome-wide copy number 
analysis, we were able to map the breakpoints of altered chromosomal regions in 
higher detail than in the previous studies, and novel regions of copy number gains 
were also identified. Furthermore, distinctive patterns of copy number alterations 
emerged for different histological subtypes of gastric cancer as well as for cancers 
located in different parts of the stomach. This suggests that different molecular 
backgrounds exist for these cancer subtypes. The intestinal gastric cancer-associated 
gains  at  Xp  and  diffuse  gastric  cancer-associated  gains  at  19q13.32  have  not  been  
reported prior to this study. Moreover, copy number alterations of individual genes 
were detected that discriminated the intestinal from the diffuse gastric cancers as 
well as antrum-located gastric cancers from those located in the corpus.  
  The impact of copy number alterations on gene expression was significant, as 
6-10% of genes located in chromosomal regions of gains and losses also showed 
concomitant alterations in their expression. Integration of genome-wide aCGH and 
gene expression microarray data proved to be an effective method in highlighting 
gastric cancer-related genes since the results from the integration analysis could be 
further validated using tissue microarrays, TRAC assay, and real-time qRT-PCR 
analysis. All of the validated genes showed statistically significant alterations in their 
expression in gastric cancer compared with normal gastric tissue. In addition, SPP1 
was overexpressed in metastasized gastric tumors. Interestingly, the overexpression 
of one of the genes identified in Study III, CXCL1, was also associated with an 
improved  survival  of  gastric  cancer.  Further  studies  of  CXCL1 will show the clinical 
significance of this gene. 
Genome-wide gene expression analysis of Finnish and Japanese gastric 
tumors revealed gastric cancer-specific gene expression signatures that clearly 
discriminated between gastric cancers and normal gastric tissues. Patients from 
three different populations and data from three different microarray platforms 
(Agilent 1- and 2-color and Affymetrix 1-color gene expression arrays) were 
combined to identify common gastric cancer-related gene expression signatures. 
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Genes identified as differentially expressed in different patient populations and with 
different microarray platforms could prove to be the most robust and the most 
promising clinical biomarker candidates for gastric cancer. None of the previous 
gastric cancer gene expression studies have integrated genome-wide gene 
expression data in this manner. Altogether, several known as well as novel genes 
were identified in Studies I-III that may prove to be critically important for gastric 
carcinogenesis. Functional validation of these genes may lead to novel biomarkers 
for gastric cancer diagnosis as well as for targeted therapy.  
Genomic profiling of human tumors has opened completely new avenues for 
targeted treatment as well as for cancer classification, diagnostics, and prediction of 
clinical outcome (Golub et al., 1999; Alizadeh et al., 2000; Sorlie et al., 2001; Gordon 
et al., 2002; Pomeroy et al., 2002; Rosenwald et al., 2002,; Van’t Veer et al., 2002; 
Vecchi et al., 2007).  However,  the  vast  amount  of  information  produced  by  
microarrays poses a challenge for differentiating those molecular alterations that 
contribute to carcinogenesis from those that are simply innocent bystanders (Chin 
and Gray, 2008).  
Gastric tumors constitute a heterogeneous group of tumors, and current 
surgical approaches, radiation, and chemotherapies benefit only a subset of these 
patients. A genomic-based approach is one of the most promising tools for 
developing new targeted therapies for different patient subgroups and for predicting 
clinical outcome and responses to the current treatment modalities. Genome-wide 
microarray analyses have identified a number of genes that are suggested to play a 
role in gastric carcinogenesis. Specific gene expression patterns correlate with 
histology (Hippo et al., 2002; Boussioutas et al., 2003; Chen et al., 2003; Kim et al., 
2003; Jinawath et al., 2004),  invasiveness (Hasegawa et al., 2002; Hippo et al., 2002), 
and  survival  (Chen  et  al., 2003; Tay et al., 2003;  Vecchi  et  al., 2007). Despite the 
advances in molecular profiling of gastric cancer, these results are not directly 
translatable into clinical practise. However, many of the genes identified, especially 
ERBB2, show great promise for future treatment of gastric cancers (Roukos and 
Kappas, 2005).  
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